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A STUDY ON MICROBIOLOGICAL PROFILE OF SYMPTOMATIC 
CATHETER ASSOCIATED URINARY TRACT INFECTION IN AN 
INTENSIVE CARE UNIT SETUP IN A TERTIARY CARE HOSPITAL  
ABSTRACT 
Introduction: Catheter associated urinary tract infection (CAUTI) is an important 
healthcare associated infection. More than 80% of nosocomial UTIs are catheter-
associated. Patients in intensive care unit have more risk of acquiring CAUTI.  
Aim & Objectives: To determine the incidence rate of symptomatic  catheter associated 
urinary tract infection in intensive care unit set-up, to isolate the organisms involved in 
symptomatic CAUTI, to determine the antimicrobial sensitivity pattern of the isolates, 
to determine the association of symptomatic CAUTI in relation to high risk factors 
Materials & Methods: A total of 100 patients admitted in medical ICU and put on 
Foley’s catheter were included in the study and followed up for the development of 
symptomatic CAUTI. The urine samples from the catheter were collected on day 1 and 
then on day 3,5,7,10,14 and every weekly till the patient was discharged, expired, 
catheter removed or developed bacteriuria. The samples were processed as per standard 
guidelines. 
Results: Total 26 patients developed Symptomatic CAUTI, thereby the incidence being 
26 %. Pseudomonas aeruginosa was the commonest isolate (25%) followed by 
Klebsiella pneumoniae (17.5%), Escherichia coli, Enterococcus faecalis and Candida 
spp. (15%) each. P.stutzeri comprised 5% and Klebsiella oxytoca, P.fluorescens and 
Staphylococcus aureus 2.5% each. High degree of antibiotic resistance was observed 
.On the whole the bacterial isolates were more sensitive to piperacillin-tazobactam, 
imipenem and meropenem. 
Conclusion: Development of CAUTI is common in critically ill patients Emphasis 
should be placed on good catheter management and reducing the duration of 
catheterization to reduce its incidence. Knowledge of resistant pattern can help in 
implementing proper antibiotic therapy and infection control policy. 
 
Key words: catheter associated UTI, nosocomial 
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INTRODUCTION 
Catheter associated urinary tract infection (CAUTI) is an important healthcare 
associated infection. Urinary tract infection (UTI) is the most common nosocomial 
infection which accounts for as many as 35% [1] of the cases. Among these, more than 
80% of nosocomial UTIs are catheter-associated (CAUTI) [1]. As compared to patients 
in non-critical area, those in intensive care unit have more risk of acquiring CAUTI [2, 
3].  
Healthcare associated infection (HAI) has emerged as an important health 
problem throughout the world, causing significant mortality and morbidity [4]. HAI is 
defined as clinical infection that develops after 48 hours of admission to a hospital for 
treatment of a different initial illness. These infections were neither overtly present nor 
within the incubation period at the time of admission, and are often due to organisms 
endemic in the hospital [5].  
If a patient has an indwelling catheter for 48 hours or more and then develops 
signs and symptoms of UTI, it is considered as symptomatic CAUTI. If the catheter was 
removed after 2 days and  the UTI criteria is fulfilled on the day of removal or the next 
day, then  also it is considered CAUTI. It is of 2 types: Symptomatic & Asymptomatic 
bacteremic CAUTI.  Symptomatic CAUTI is considered when symptoms / signs 
consistent with UTI exists along with bacteriuria in a catheterized patient. [6] The signs 
and symptoms either are localized to the urinary tract or can include otherwise 
unexplained systemic manifestations, such as fever. The accepted threshold for 
bacteriuria varies from 103 cfu/mL to 105 cfu/mL [61]. 
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 The source of infection can either be endogenous or exogenous. The presence 
of meatal, rectal, or vaginal colonization by microorganisms causes endogenous 
infection. Exogenous infections occur during insertion or manipulation of the catheter 
and collecting system by health personnel [6]. Even after using closed, sterile drainage 
system and inserting the catheter aseptically, patients still acquire the infection [7].  
A number of risk factors are implicated in the causation of CAUTI. These 
include female sex, old age, increased duration of hospital stay and catheterisation, 
impaired immunity, severe underlying illness, diabetes mellitus, renal dysfunction, 
incontinence, neurological/orthopaedic causes, disconnection of drainage system and 
faulty catheter care [6, 8]. 
The causative organisms include Gram negative bacilli (GNB), Gram positive 
bacteria and even Candida spp. Earlier the most common organism was Escherichia 
coli. Recent studies indicate a shift towards non-fermentative GNBs, Enterococcus spp. 
and Candida spp.  
CAUTI can produce a wide range of complications. These include fever, 
urethritis and cystitis in mild cases and acute pyelonephritis, renal scarring, calculi 
formation and bacteremia in severe cases. It can also cause prostatitis, epididymitis, and 
orchitis in males. Other less common complications include septic arthritis, 
endocarditis, vertebral osteomyelitis, septic arthritis, etc.[6].  
Due to intense microbial exposure, antimicrobial resistant organisms are 
frequently isolated in these cases. CAUTIs constitute a huge reservoir of antimicrobial 
resistance and inadvertent use of antibiotics increases the risk of cross-infections among 
catheterized patients. This results in prolonged hospital stay and increased cost of 
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healthcare, not only to the patients but also to the hospital. Ultimately there is overall 
increased morbidity and mortality.  
Due to increase in prevalence of multidrug resistant isolates, early detection is 
crucial. This study will help in planning effective infection control policies and proper 
antimicrobial policy, thereby decreasing the incidence of antimicrobial resistance.  
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AIMS AND OBJECTIVES 
1. To determine  the incidence rate of symptomatic  catheter associated urinary tract 
infection in intensive care unit set-up 
2. To isolate the organisms involved in symptomatic CAUTI 
3. To determine the antimicrobial sensitivity pattern of the isolates. 
4. To determine the association of symptomatic CAUTI in relation to high risk 
factors 
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REVIEW OF LITERATURE 
ANATOMY OF URINARY TRACT [9,10,11] 
The urinary tract includes kidneys, ureters, urinary bladder and urethra. The 
role of the kidneys is excretion of the waste products of metabolism, maintenance of 
water and electrolyte balance of the body and the acid–base balance of the blood.  
The kidneys are reddish brown, bilaterally paired organs present in 
retroperitoneum. The upper pole of each kidney lies opposite 12th thoracic vertebra and 
lower pole opposite 3rd lumbar vertebra. The right kidney lies slightly lower than the 
left kidney due to the presence of right lobe of the liver.  
The ureters extend from the kidneys to the posterior surface of the urinary 
bladder. Each ureter measures about 25 cm long. Due to peristaltic contractions of the 
muscle coat, urine gets propelled along the ureter, assisted by the filtration pressure of 
the glomeruli.  
 
Fig 1: Anatomy of the urinary tract[1] 
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 The urinary bladder is situated within the pelvis behind the pubic bones. 
It stores urine and in the adult has a maximum capacity of about 500 ml. The empty 
bladder is pyramidal, having an apex, a base, and a superior and two inferolateral 
surfaces; it also has a neck which lies just below the level of the upper border of the 
symphysis pubis. The base, or posterior surface of the bladder, faces posteriorly and 
is triangular. The superolateral angles are joined by the ureters, and the inferior angle 
gives rise to the urethra. The ureters pierce the bladder wall obliquely, and this provides 
a valve like action, which prevents a reverse flow of urine toward the kidneys as the 
bladder fills. 
The urethra in males longer than females and measures 20 cm. It is divided into 
three parts: prostatic urethra, membranous urethra and penile urethra. Whereas, the 
urethra in females about 3.8 cm long.  
Anatomically, the urinary tract is divided as upper and lower urinary tract: lower 
implies the bladder and urethra, and the upper urinary tract implies ureters and kidneys. 
TYPES OF URINARY TRACT INFECTION[1,10] 
Any inflammatory response of the urothelium to bacterial invasion is UTI. It is usually 
associated with bacteriuria and pyuria. 
a) Based on the presumed site of origin, UTI can range from cystitis, pyelonephritis 
to urethritis. 
b) Based on the anatomic location of the infection, UTI is classified as:  
i. Upper UTI - It affect the ureters (ureteritis) or the renal parenchyma 
(pyelonephritis).  
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ii. Lower UTI- It may affect the urethra (urethritis), the bladder (cystitis), or 
the prostate in males (prostatitis).  
c) Based on the health of the host and anatomic/functional status of urinary tract, 
UTI can be: 
i. Uncomplicated UTI- it occurs when the urinary tract is structurally and 
functionally normal and the host is not compromised. 
ii. Complicated UTI- Here the urinary tract is structurally or functionally 
abnormal, the host is compromised and/or the bacteria have increased 
virulence or antimicrobial resistance. 
CATHETER ASSOCIATED URINARY TRACT INFECTION (CAUTI) AND 
ITS DIAGNOSIS [6,12,13] 
An indwelling catheter, also known as Foley’s catheter, is a drainage tube that is 
inserted into the urinary bladder through the urethra, is left in place, and is connected to 
a drainage bag (including leg bags. Condom or straight in-and-out catheters, 
nephrostomy tubes or suprapubic catheters are not included. The indwelling urinary 
catheters are made up of tuber latex or silicon. They are essential components of modern 
medical care and are used in acute care setting and extended care facilities. 
Unfortunately, they significantly increases the risk of iatrogenic infection 
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Fig 2: Foley’s catheter[13] 
Catheter associated urinary tract infection as a UTI where an indwelling urinary 
catheter was in place for >2 calendar days on the date of event, with day of device 
placement being Day 1, and an indwelling urinary catheter was in place on the date of 
event or the day before. If an indwelling urinary catheter was in place for > 2 calendar 
days and then removed, the UTI criteria must be fully met on the day of discontinuation 
or the next day.  
  If in a patient develops UTI within 48 hours of discharge from a location, 
The infection is attributed to the transferring location or facility. This is known as the 
“transfer rule”.  
 In case the Foley’s catheter is discontinued and reinserted and one full day passes 
between the two events, then the day count should be started anew. Otherwise the day 
count continues from the previous catheter. 
It is of 2 types: Symptomatic CAUTI & Asymptomatic bacteremic CAUTI. UTI 
has more typically been assumed to imply symptomatic disease that warrants 
antimicrobial therapy. 
 Symptomatic CAUTI: [6] It is diagnosed as: 
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1. Patient had an indwelling urinary catheter >2 days & at the time of specimen 
collection(day of event)    
    and  
 at least 1 of the following signs or symptoms:  
 fever (>38°C); 
 suprapubic tenderness; 
 costovertebral angle pain or tenderness (With no other recognized 
cause)  
and  
 a positive urine culture of ≥105 CFU/ml and with no more than 2 species 
of microorganisms. 
2. Patient had an indwelling urinary catheter  for >2 days & had it removed the day 
of or the day before ,  
    and 
 at least 1 of the following signs or symptoms: 
 fever (>38°C);  
 suprapubic tenderness;  
 costovertebral angle pain or tenderness (With no other recognized 
cause) 
 urgency,  
 frequency,  
 dysuria,  
    and  
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 a positive urine culture of ≥105 CFU/ml and with no more than 2 species 
of microorganisms. 
3. Patient had an indwelling urinary catheter >2 days &  at the time of specimen 
collection   
    and  
 at least 1 of the following signs or symptoms:  
 fever (>38°C);  
 suprapubic tenderness;  
 costovertebral angle pain or tenderness (With no other recognized cause)  
     and  
 a positive urine culture of ≥103 & ≤ 105 CFU/ml and with no more than 2 
species of microorganisms. 
      and 
 at least one of the following findings: 
i. Positive dipstick test for leukocyte esterase &/nitrite 
ii. Pyuria (urine specimen with ≥10 white blood cells [WBC]/mm3 of 
unspun urine or >5 WBC/high power field of spun urine) 
iii. Microorganisms seen on Gram’s stain of unspun urine 
4. Patient had an indwelling urinary catheter  for >2 days & had it removed the day 
of or the day before ,  
    and 
 at least 1 of the following signs or symptoms:  
 fever (>38°C);  
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 suprapubic tenderness;  
 costovertebral angle pain or tenderness (With no other recognized cause)  
 urgency,  
 frequency,   
 dysuria 
    and  
 a positive urine culture of ≥103  & ≤ 105 CFU/ml and with no more than 2 species 
of microorganisms.  
    and 
 at least one of the following findings: 
i. Positive dipstick test for leukocyte esterase &/nitrite 
ii. Pyuria (urine specimen with ≥10 white blood cells [WBC]/mm3 of 
unspun urine or >5 WBC/high power field of spun urine) 
iii. Microorganisms seen on Gram’s stain of unspun urine 
EPIDEMIOLOGY OF CATHETER ASSOCIATED URINARY TRACT 
INFECTION 
  Across the world, over 100 million urinary catheters are being used annually. 
This turns out to be almost 200 being used every single minute [14,15]. 
 Up to 25% of hospitalized patients are catheterised. Though it is a necessary 
intervention, indwelling catheters are a leading cause of nosocomial infection[16]. 
Various studies have shown that 75 to 80% of all nosocomial urinary tract infections 
occur following catheter insertion.[17] 
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   Most CAUTIs are benign, in 30-40% of patients, a systemic complication like 
gram negative bacteremia can develop. So, to decrease the expenses secondary to 
infection and morbidity and mortality rate, prevention of CAUTI and its complications 
is very essential.[18] 
 CAUTIs in hospitalized patients are most likely to be caused by 
Enterobacteriaceae such as Escherichia coli, Klebsiella spp. and Proteus species, 
Staphylococcus species, Pseudomonas aeruginosa and Enterococcus species.[1] 
  The organisms causing urinary tract infections vary from one geographical 
area to another. The increased prevalence of UTIs caused by some highly resistant 
pathogens and the changing resistance pattern of isolates from time to time is due to 
catheterisation.[16] 
 In ICUs, nosocomial infections are common due to frequent use of wide-
spectrum antibiotics, presence of comorbid conditions and increased use of invasive 
interventions and. In developing countries, the rate of healthcare associated 
infections and bacterial resistance are 3 to 5 times higher than international 
standards.[19] 
RESIDENT MICROORGANISMS OF URINARY TRACT [1, 20, 21] 
The normal commensals of the urethra are lactobacilli, corynebacteria, and 
coagulase-negative staphylococci. All areas of the urinary tract above the urethra in a 
healthy human are sterile. The resident microflora include: 
• Coagulase-negative staphylococci (excluding S. saprophyticus) 
• Viridans and non-hemolytic streptococci 
• Lactobacilli 
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• Diphtheroids (Corynebacterium spp.) 
• Nonpathogenic (saprobic) Neisseria spp. 
• Anaerobic gram-negative bacilli 
• Anaerobic cocci 
• Propionibacterium spp. 
• Commensal Mycobacterium spp. 
• Commensal Mycoplasma spp. 
ETIOLOGICAL AGENTS OF CAUTI[1,21] 
The presence of a foreign body in the urinary tract increases the chances of 
CAUTI. The pathogens are acquired mainly from the hospital niche such as E. coli, 
Klebsiella spp., Proteus spp., staphylococci, other Enterobacteriaceae, Pseudomonas 
aeruginosa, enterococci, and Candida spp.  
PATHOGENESIS [1,7,22] 
The Foley’s catheter interferes with the natural defences of the urinary tract. 
Routes of infection:  
Urine is typically sterile. There are three main routes for the entry of organisms 
into the urinary tract: ascending, haematogenous and lymphatic. CAUTI is mainly an 
ascending infection. Though innate mechanisms prevent infection, these pathogens can 
cause infection because they colonise urinary catheter and/or mucosal site, evade host 
defences and replicate and damage the host cells. Patients become colonised with 
microorganisms endemic to the hospital soon after hospitalisation which carry resistant 
markers. These organisms colonise different areas of the patient such as skin, 
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gastrointestinal tract and mucous membrane. Organisms may cause CAUTI in one of 
two ways:  
a. Extraluminal ascending infection- It can occur either during the time of 
indwelling catheter insertion, or later on from the perineal area. The external 
surface of the Foley’s catheter is coated by a thin mucous film in which the 
organisms can move upwards by capillary action. This extraluminal route is 
responsible for 66% of CAUTI. 
b.  Intraluminal infection – Here, the organisms enter the lumen of the catheter 
due to manipulation of the catheter system. Either the closed drainage system 
is not maintained or the urine in the collecting bag gets contaminated. It is 
responsible for 34% of the cases. 
These organisms multiply and then ascend through ureters to the kidneys once they 
reach the bladder. 
 
Fig 3: Routes of infection of CAUTI [22] 
15 
 
Host parasite relationship:[1,7] 
 Indwelling pathogens favour the colonisation of uropathogens due to the 
following factors: 
a) Enhancing microbial adhesion- The bacteria recognise the surface of the 
catheters by adhesins and attach to the host cell binding receptors. 
b)  The protective uroepithelial mucosa get damaged while inserting catheter, thus 
exposing new binding sites for adhesins. 
c) Indwelling catheter disrupts the normal host mechanical defences. Residual urine 
due to overdistension of bladder and incomplete voiding, favours microbial 
growth. 
Fewer virulence factors are required by organisms which cause CAUTI. 
The various bacterial virulence factors are: 
1. Bacterial adhesins- These help in attaching to the host cell receptor. The 
adhesins overcome the electrostatic repulsion present between bacterial cell membrane 
and surfaces, thus allowing intimate interactions. During the infection, these factors are 
expressed differentially. They recognise specific host cell surfaces, cell types and 
extracellular membrane proteins and also evade the host immune response. Gram 
negative uropathogens have adhesinson the tip of fimbriae or pili and non-fimbrial 
adhesins. 
2. Biofilm formation- They start to change phenotypically and produce 
exopolysaccharide after attaching to the surface of catheter and urothelium. These 
entrap and protect these pathogens. They multiply and form microcolonies and mature 
into biofilms. 
16 
 
The advantages of biofilm are: 
a) There is exchange of genetic material among the organisms within the 
biofilm which causes acquisition and spread of antibiotic resistant genes and 
other characteristics. 
b) It protects the uropathogens from antimicrobials and host immune 
response. 
c) The biofilm aggregates are sheared and daughter cell from actively 
growing cells are shed. This causes seeding and infection of bladder and 
catheter. 
3. Motility – Motility of the bacteria mediated by flagella and type IV pilus helps 
in spreading the infection from the initial colonisation site to the urinary tract. 
4. Toxins- The organisms adapt to the urinary tract environment on colonising on 
the catheter and urothelium. Due to degradative enzymes and toxins produced by them 
tissues are broken down and nutrients released.  
5. Iron acquiring systems- Various iron acquisition systems such as ferric and 
ferrous ion transport systems, heme transporters, and siderophore iron uptake system 
are developed by the organisms. 
6. Urea utilisation- Many bacteria utilise urea as a nitrogen source present in 
human urine. Hydrolysis of urea alkalinises the urine and cause precipitation of 
polyvalent ions. These get enmeshed and form crystalline biofilms which protect the 
biofilm associated bacteria from antimicrobial agents. 
7. Evasion of host immune response-  
a) Production of capsule 
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b) Immunoglobulin A proteases 
c) Lipopolysaccharides-They help in resisting antimicrobial peptides and 
complement-mediated lysis. 
Risk factors :[22,23] 
Various risk factors are attributed for the causation of CAUTI. These include: 
1. Duration of catheterisation – Foley’s catheter can be short-term (in situ less 
than 28 days), or long-term (in situ greater than 28 days). The risk of acquiring an 
infection increases by 5% each day. 
2. Female gender - The anatomy of the female urethra is significantly important 
for the pathogenesis of UTIs as it is relatively short compared with the male urethra and 
also lies in close proximity to the warm, moist, perirectal region, which has abundant 
microorganisms. So, in females, the pathogens can reach the bladder more easily. For 
men, the incidence of urinary tract infections increases after the age of 60 because the 
enlarged prostate causes incomplete voiding of urine. 
3. Diabetes mellitus 
4. Underlying neurological disease  
5. Respiratory diseases such as COPD 
6. Urological/ nephrological diseases 
7. Steroid use and other immunocompromised conditions 
INDICATIONS FOR CATHETERISATION [22] 
Some of these include relieving urinary retention, assist in achieving patient 
immobilisation in case of fractures, monitor urinary output in critically ill patients, 
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instillation of drugs or during urology investigations and for patient comfort during end 
of life care. 
COMPLICATIONS OF FOLEY’S CATHETERS [23,24] 
The presence of indwelling catheter leads to various infections such as cystitis, 
pyelonephritis, secondary bacteremia/sepsis or late onset sequellae, e.g. metastatic 
osteomyelitis and meningitis. 
As a result, hospital stay is prolonged and there is emergence of multidrug resistant 
organisms, thereby increasing morbidity, mortality and health cost. 
LABORATORY DIAGNOSIS [1,8,21,25] 
1. Specimen collection- Strict aseptic technique should be followed while 
collecting urine specimen from patients with indwelling catheters. Gloves should be 
worn by healthcare workers.  The sample should be collected ideally from the sampling 
port. If sampling port is not present, then the catheter tubing should be clamped off 
above the port and the wall of the tubing cleaned with 70% ethanol. The urine is then 
aspirated using a needle and syringe. Minimum 3 ml of the urine sample should be 
collected from Foley’s catheter. There should not be any disruption of the closed 
drainage system. Specimens obtained from the collection bag are inappropriate, because 
organisms can multiply there, obscuring the true relative numbers. 
 
2. Specimen transport- Urine must be immediately transported to the lab within 2 
hours of collection or must be immediately refrigerated or preserved.  
When there is a delay in the transport of urine sample for more than 2 hours, 
boric acid (0.1g/10 ml of urine) is used as a preservative. Such specimens need not be 
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refrigerated. At this concentration of boric acid, bacteria remain viable without 
multiplying for 48 hours, however it may inhibit some Enterococci and Pseudomonas 
spp. 
Urine must not be preserved with a bactericidal chemical such as thymol, 
bleach, hydrochloric acid, acetic acid or chloroform. 
For patients from whom colony counts of organisms of less than 100,000/mL 
might be clinically significant, plating within 2 hours of collection is recommended. 
The kits provide a convenient method for preserving and transporting urine from remote 
areas where refrigeration is not practical. 
3. Specimen processing 
a. Screening procedures- As a major portion of urine specimens may 
contain no etiologic agents of infection or contain only contaminants, procedures have 
been developed to identify quickly those urine specimens that will be negative on 
culture and circumvent excessive use of media, technologist time, and the overnight 
incubation period are discussed in this section. A reliable screening test for the 
presence or absence of bacteriuria provides physicians important same-day 
information that a conventional urine culture may take a day or longer to provide. Many 
screening methods have been advocated for use in detecting bacteriuria and/or pyuria. 
These include microscopic methods, colorimetric filtration, bioluminescence, 
electrical impedance, enzymatic methods, photometric detection of growth, and 
enzyme immunoassay.  
Some of these are: 
20 
 
i. Gram stain – A Gram stain of urine is an easy, inexpensive means 
which provides immediate information about the infecting organism and thereby guides 
empiric therapy. The performance characteristics of the urine Gram stain are not well 
defined because different criteria have been used to define a positive result (1 or 5 
bacteria per OIF). Using either 1 or 5 bacteria/OIF has a sensitivity of 96% and 95%, 
respectively, and a specificity of 91% when correlated with significant bacteriuria (>105 
CFU/mL).  
The Gram stain should not be used for detecting polymorhonuclear neutrophils 
(PMNs) in urine because leukocytes deteriorate quickly when the urine is not fresh or 
not adequately preserved. 
ii. Pyuria- The presence of pus cells in urine signifies inflammation. 
These can be detected and enumerated in uncentrifuged or centrifuged specimens. In 
urine sediments, white blood cells (WBC) are usually reported as: 
Few: Up to 10 WBCs/HPF (high power field, i.e. using 40x objective) 
Moderate number: 11–40/HPF 
Many: More than 40 WBC/HPF 
A few pus cells are normally excreted in urine. Pyuria is significant when more than 10 
WBC/µl of urine are present. 
iii. Nitrate reductase test- This detects the presence of nitrites in the 
urine. The pathogens belonging to the family Enterobacteriaceae reduce nitrate to 
nitrite by the enzyme nitrate reductase. This is detected by the Greiss test or a nitrite 
reagent strip test, provided the organisms are present in sufficient concentration. The 
test is negative when the organisms are few or the pathogen are Enterococcus faecalis, 
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Pseudomonas species, and Candida spp. which do not reduce nitrate to nitrite. A 
positive nitrite test shows development of pink- red colour. 
iv. Leucocyte esterase test- The evidence of a host response to 
infection is the presence of PMNs in the urine. Leukocyte esterase enzyme is specific 
for PMNs. This test detects the enzyme from both active and lysed WBCs. The nitrate 
reductase and leukocyte esterase tests have been incorporated into a reagent paper strip. 
False negative results can occur when the urine contains boric acid or 
excessive amount of protein (>500 gm/100ml) or glucose (> 2 gm/100ml). Unreliable 
results can also occur when urine contains nitrofurantoin of gentamicin. 
b. Urine culture- Urine culture can be performed by semi-quantitative 
method, quantitative method and automated system 
 Semi-quantitative method- 
 Standard loop method-The urine should be mixed thoroughly before 
plating. Inoculation of the plates is done using disposable sterile plastic tips calibrated 
to deliver a constant amount or calibrated loop which delivers either 0.1 or 0.01 ml of 
urine. 
The calibrated loop that delivers 0.01 mL of urine is recommended to detect 
lower numbers of organisms in certain specimens such as samples from Foley’s 
catheters, nephrostomies, ileal conduits, and suprapubic aspirates should be plated with 
the larger calibrated loop. The media used are either Cysteine lactose electrolyte 
deficient (CLED) or 5 % sheep blood agar and Mac Conkey agar. The inoculated plates 
are incubated for at least 24 hours at 35° to 37° C in air. Colonies are counted on each 
plate. The number of CFUs is multiplied by 1000 (if a 0.001-mL loop was used) or by 
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100 (if a 0.01-mL loop was used) to determine the number of microorganisms per 
millilitre in the original specimen. Plates with no growth are incubated for total of 48 
hours before discarding them. 
 Filter paper method- This method uses a standard 6mm wide strip of 
blotting paper or filter paper. It is bent into L-shape with a 12mm long foot and sterilised 
at 160 °C for one hour. The whole of the angulated end and foot is dipped in the 
uncentrifuged urine sample and then withdrawn and waited for few seconds so that the 
excess of urine is absorbed on the filter paper. The foot of the paper is then pressed on 
the culture medium so that the whole area of the foot makes contact with the medium. 
The strip is removed and discarded in the disinfectant. The plate is read after overnight 
incubation for the number of colonies. Up to 50 colonies can be counted and heavier 
growths are designated as confluent (++) or semi-confluent (+). A count of 25 colonies 
of bacilli and 30 colonies of cocci corresponds to 105 bacteria/ml count. 
 Dip slide method- The dip slide is a small plastic tray which contains a 
layer of the appropriate culture medium. The dip slide is withdrawn and briefly 
immersed in the urine container. On removing, any excess of the urine is removed 
against the wall of the urine container and the dip slide is then replaced in its container. 
It is incubated overnight at 37° C. the count of viable bacteria is estimated from the 
number of colonies or the pattern of confluent or semi-confluent growth. Commercial 
suppliers provide charts showing representative numbers and patterns. By comparing 
with it, the viable count can be read. 
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 Quantitative method [26]- This includes pour plate method and 
Miles & Misra method. These methods measure CFU/ml which gives the count of 
viable bacterial or fungal cells.  
In Miles and Misra method, nutrient agar plates are used which are divided into 
four. Three serial dilutions - one in ten, one in one-hundred and one in one-thousand 
are made of the sample and two drops (20 µl each) of the original sample and the 
dilutions are inoculated into the quadrants of each plate. The plates are incubated 
overnight and inspected for growth. Separate colonies that are countable will be seen 
in one of the four quadrants.  
An average of the counts on the five plates is made. The CFU/ml is calculated 
using the formula:  
                cfu/ml = (no. of colonies x dilution factor) / volume of culture plate 
 Automated system[27]-Sidecar, Alfred 60AST and HB&L are the first 
automated systems for the rapid urine culture. These have high sensitivity and 
specificity. The technology based on light scattering is used. They can monitor the 
bacterial replication activity and provide real time growth curves. After only 45 minutes 
of incubation, strong positive samples get flagged. Only live bacteria are detected in 
this method. The interference from erythrocytes, leucocytes, dead cells and salts present 
in the sample are eliminated during the initial zero reading 
PREVENTION OF CAUTI[7] 
The various measure to prevent CAUTI include: 
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1. Avoid unnecessary catheterization- The indwelling catheter use should 
be limited to those patients who really require catheterisation. If required for more than 
a week, the urinary catheters should be changed every 8 to 10 days to reduce the risk 
of infection. The drainage bags should be emptied at a minimum of every 4 to 6 hours 
to avoid bacteria entering the catheter lumen.   
2. Select alternative catheterization procedures- Alternative methods of 
catheterisation such as condom and suprapubic catheters and intermittent 
catheterisation should be considered.  
3. Maintenance of a closed drainage system and proper use of catheter- 
Proper aseptic technique should be used for the insertion the urinary catheter. A closed 
catheter system must be maintained. The catheter and the drainage tube should not be 
disconnected at any time. The correct size of the catheter should be used. Smaller 
catheters (14 French and 16 French) and 5 ml balloons are preferred because the larger 
catheters tend to increase the amount of residual urine and cause reinoculation of the 
bladder. There are chances of blockage of paraurethral glands, urethral irritation and 
erosion.  
4. Eliminate bacterial colonization of the meatus- Proper meatal care 
should be done with daily cleansing with soap and water or with povidone- iodine 
solution followed by povidone-iodine ointment. It should be done at least twice daily. 
5. Development of new biomaterials for catheter- Hydrophobicity of the 
organisms and biocompatible surface of the catheter determines bacterial adhesion. 
Biomaterial such as silicone, polyurerhrane, composite biomaterial or hydrogen coated 
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material have been studied for preventing colonisation of catheter and biofilm 
formation. 
6. Use of antimicrobial agents on catheter materials- Preventive 
measures such as application of antimicrobial solutions, antiseptics and lubricants on 
the catheter surface and the addition of antimicrobial agents in the collection bag have 
been studied but have not proven any benefit. 
7. Use of probiotics- Adding non-pathogenic strains into the bladder can 
prevent symptomatic infection by bacterial interference and hindering uropathogen 
colonisation. 
8. Newer technologies- Newer approaches such as  the sensing of bacterial 
encrustation, use of biofilm inhibitors, development of hydrophilic and nutrient-
scavenging biomaterials, and use of low-energy surface acoustic waves have been 
developed. 
Catheter bundle care is followed to reduce the incidence of catheter associated 
urinary tract infection [28] . These include: 
 Appropriateness of the indication for catheterisation 
 Monitoring of maintenance of closed drainage system 
 Routine daily meatal hygiene 
 Routine emptying of drainage bags 
 Use of proper hand hygiene, gloves and apron before each catheter care 
procedure. 
TREATMENT[7] 
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Asymptomatic bacteriuria is inevitable in catheterised patients. So, its treatment 
is usually not recommended. Also, it may cause selection of resistant strains and 
emergence of multidrug resistant organisms.  
Treatment of Symptomatic CAUTI is challenging as these are usually 
polymicrobial in nature especially in long-term catheterised patients and due to the 
presence of antimicrobial resistance and biofilm formation. Most of the patients are 
treated with antimicrobials for 10-14 days usually with parenteral antimicrobials. In 
case of monomicrobial infection and short term catheterisation, treatment consists of 
single drug therapy. Catheterised patients who are seriously ill and those with 
polymicrobial infection and long-term catheterisation require two drug regime. Once 
antimicrobial therapy has been administered, the indication of clearance of infection is 
resolution of symptoms and not the absence of bacteriuria. 
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MATERIALS AND METHODS 
ETHICAL CONSIDERATION:  
 Approval of the Institutional Ethics Committee was obtained before starting the 
study. Informed written consent was taken from all the patients included in the study. 
STUDY SETTING: 
Study Design: Cross-sectional study 
Study duration: One year- October 2014 to September 2015 
Sample size: 100 patients 
Study Group: Patients admitted to medical ICU and put on Foley’s catheter 
 Place of study: The study was conducted at the Institute of Microbiology, 
Madras Medical College in association with Medical ICU, Rajiv Gandhi Government 
General Hospital, Chennai. 
INCLUSION CRITERIA: 
• Age ≥ 18years 
• Patient admitted to IMCU and put on Foley’s catheter.  
EXCLUSION CRITERIA: 
• Patients <18 years of age 
• Patients catheterised prior to admission in ICU 
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• Those patients, whose Foley’s catheter were removed or who were 
discharged/expired before 3rd day of catheterization  
• Those who were confirmed to have UTI on Day 1 
• Pregnancy 
COLLECTION OF DATA[8]:  
Data were collected from the patients included in the study using a preformed 
structured questionnaire. Details such as name, age, sex, address, IP no., date of 
admission, clinical data like presenting complaints, personal history, past medical 
history, high risk factors, immunocompromised status, physical examination findings 
and details of clinical diagnosis were collected. Indication for Foley’s catheter was 
noted.  Daily examination of the patients were done to look for any evidence of urinary 
tract infection such as fever, suprapubic tenderness and costovertebral angle tenderness. 
Catheter care in the form of daily meatal care by betadine or soap water and 
maintenance of closed drainage were frequently monitored. The patients were followed 
till they developed bacteriuria or discharged, expired or catheter was removed. The date 
of catheter removal and duration of catheterization was noted. Patients who were shifted 
to different ward were followed for up to 48 hrs for the developments of symptoms of 
CAUTI. 
COLLECTION OF URINE SAMPLE(1,8]: 
Urine specimens were collected aseptically. The Foley’s catheter was first 
clamped above the bifurcation and then disinfected with spirit. Using a sterile syringe 
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24-gauge needle, approximately (minimum) 3ml of urine was taken as a sample from 
above the area clamped, in a flat bottomed universal container. 
The samples were taken to laboratory within 1 hour of collection. Day 1 sample 
was taken to rule out prior presence of UTI. The samples were repeated on 3rd, 5th, 7th, 
10th, 14th day and then every weekly until catheter removal, or patient developed 
bacteriuria, or until discharge/death of the patient. 
SAMPLE PROCESSING [1,21]: 
1. Direct Gram’s stain of uncentrifuged urine- A loopful of urine was taken on a 
clean, sterile glass slide, smear prepared and Gram stained. It was air dried and 
observed under oil immersion lens for the presence of bacteria or candida. Presence of 
one microorganism per oil immersion field indicates bacterial count of >105/ml of 
urine. 
2. Dipstick for leukocyte esterase and/or nitrite- DIRUI H-10 urinalysis strips [29] 
were used for detection of nitrites and leucocyte esterase. The test was done on 
uncentrifuged urine. The reagent area of the strip was immersed in the urine and 
removed quickly. Excess of urine was removed by holding the edge of the strip against 
the rim of the container. The result on the strip was compared with the colour chart on 
the bottle label. 
3. Wet mount for WBC – The urine sample was centrifuged at 3000rpm for 3-5 
minutes. The supernatant was discarded and a drop of sediment was placed on the glass 
slide and a cover slip placed to prepare a wet mount. The number of pus cells / high 
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power field was counted under 40 x objective. More than 5 WBC/hpf was considered 
significant for diagnosing CAUTI. 
4. Urine culture- The specimens were cultured by semi-quantitative method using 
Mac Conkey Agar and Blood Agar as culture medium.  
i. Inoculation of the medium [1] - The catheterized urine specimen was inoculated 
by calibrated loop method. Before inoculation, urine was mixed thoroughly and the top 
of the container then removed. A calibrated loop (4 mm loop) that delivers 0.01 mL 
volume of urine was used. It was inserted vertically into the urine in the cup and taken 
out vertically. It was then touched to the centre of the plate and the inoculum was 
spread in a line along the diameter of the plate. Without flaming or re-entering urine, 
the loop was drawn across the entire plate, crossing the first inoculum streak several 
times perpendicular to the first streak.  5% Sheep blood agar plate and Mac Conkey 
agar plate were streaked by this method. They were incubated at 37°C for minimum 
24 hours. 
ii. Interpretation of the culture – The plates were read after 24 hours of incubation 
for any growth. The number of colonies were counted. The number of CFUs was 
multiplied by 1000 to determine the number of microorganisms per milliliter in the 
original specimen. The plates with no growth or tiny colonies were incubated for an 
additional 24 hours before discarding. 
5. Identification of isolates [30,31]- The isolates were identified based on colony 
morphology in 5% sheep blood agar and Mac Conkey Agar and Gram stain of the 
smear made from the colonies.  
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i. Identification of Gram negative Bacilli- Those colonies which showed GNB 
were further subjected to preliminary tests such as motility by hanging drop method, 
catalase and oxidase tests. The GNBs that were catalase positive, oxidase negative 
were suspected to belong to the family Enterobacteriaceae.  
The GNBs which were catalase positive and oxidase positive were suspected of 
being non-fermenters. All these organisms were further speciated based on standard 
biochemical tests. These included nitrate reductase test, 1% glucose Oxidative/ 
fermentative test, indole production, Methly red test, Voges Proskauer test, citrate 
utilization, triple sugar iron test, urease production, phenyl alanine deaminase test , 
decarboxylation of lysine, ornithine  and of arginine in Moeller’s decarboxylation 
media and a series of basic sugar fermentation tests – glucose, lactose, sucrose, maltose 
and mannitol.  
The Pseudomonads were speciated based on pigment production and additional 
biochemical tests such as gelatinase test, starch hydrolysis and xylose fermentation 
ii. Identification of Gram positive cocci- Those colonies morphologically 
resembling Staphylococci were further identified by catalase test, modified oxidase 
test, tube coagulase and slide coagulase test. The biochemical tests were nitrate 
reductase, methyl red, Voges Proskauer, urease production and sugar fermentation 
tests.  
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Suspected Enterococci colonies were identified and speciated by catalase test, bile 
esculin agar, heat test, Voges Proskauer test, arginine hydrolysis and fermentation of 
sugars- arabinose, raffinose, sorbitol, mannitol and sucrose. 
iii. Identification of Candida species- Based on colony morphology on 5% sheep 
blood agar and no growth on Mac Conkey agar, the colonies were suspected to belong 
to Candida species. Gram stained smear showed Gram positive budding yeast cell with 
pseudohypahae. Candida was further speciated based on germ tube test, Dalmau plate 
culture method, Chrom agar, sugar fermentation and sugar assimilation tests.  
a) Germ tube test[32,33]- 0.5 ml of human serum was taken in a sterile test tube and 
an isolated colony of yeast was emulsified. It was incubated at 37◦C for two hours. A 
drop of this suspension was placed on a glass slide, a cover slip applied over it and 
observed under high power for the presence of germ tube formation. 
Positive - Candida albicans / Candida dubliniensis 
Negative – Non-albicans Candida spp 
b)  Dalmau plate culture technique/ cornmeal tween 80 agar[34,35]-An isolated 
yeast colony was taken from the primary culture using a straight wire. It was inoculated 
onto cornmeal agar with Tween 80 plate by making 2-3 parallel lines 3.5-4cm long and 
1-2 cm apart. The streak lines were then covered with sterile coverslip and incubated at 
25◦C for at least 48 hours. It was examined under low power and then under high power 
objective at the margin of the coverslip for the presence of hyphae, blastoconidia and 
chlamydospores. 
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Table 1:  Morphology on cornmeal tween 80 agar 
Candida 
albicans 
Pseudohyphae with clusters of round blastoconidia at the septa; 
large thick-walled, single, terminal chlamydospores. 
C.dublinensis Pseudohyphae with some true hyphae; clusters of round 
blastoconidia at the septa; pairs or clusters of large thick-walled, 
terminal chlamydospores  
C.tropicalis Abundant slender long pseudohyphae, pine forest arrangement, 
blastoconidia singly or in very small groups along pseudohyphae, 
few tear drop shaped chlamydospores may be present. 
C.parapsilosis Single or small clusters of blastoconidia; crooked or curved 
appearance of short pseudohyphae; presence of large hyphal 
elements called “giant cells”. 
C.krusei Pseudohyphae with elongated blastoconidia giving “match-stick 
appearance” 
C.kefyr Pseudohyphae with elongated blastoconidia that lie parallel 
giving “log in stream appearance”.  
C.guilliermondi Clusters of yeast cells; relatively few short pseudohyphae; small 
groups of blastoconidia  at the septa; true hyphae not produced 
C.glabrata Only small oval yeast cells with single terminal budding; no 
pseudohyphae. 
C.lusitaniae Short, distinctly curved pseudohyphae with occasional 
blastoconidia at septa. 
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c) Candida CHROM agar[32,35,36] 
             Candida spp. were sub-cultured onto Sabourauds Dextrose agar plate and was 
then streaked onto Chrom agar plate. The plates were incubated for 48 hours at 37◦C. 
The colour and morphology of the colonies were noted. 
Table 2: Appearance on Chrom agar 
Species Colour 
Candida albicans Green 
C.dublinensis Light green 
C.tropicalis Steel blue 
C.parapsilosis White to pale pink colonies 
C.krusei Large , flat, spreading pale pink colonies with matt surface 
C.kefyr Pink to lavender 
C.guilliermondi Pink to purple 
C.glabarata Smooth glossy cream to pink colonies 
C.lusitaniae Pink grey purple 
d) Sugar fermentation tests[32,33,35]- Candida spp. were subcultured in sugar free 
media at 37◦C for 24-48 hours. Then 0.2 ml suspension were added to 2% sugar 
fermentation media containing Andrade indicator. They were incubated at 30 ◦ C for 48 
to 72 hours. Fermentation was indicated by acid and gas production. The sugars tested 
were glucose, maltose, sucrose and lactose. 
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Table 3:  Fermentation Reaction 
Species Glucose Maltose Sucrose Lactose 
C. albicans AG AG - - 
C. tropicalis AG AG AG - 
C. kefyr AG AG AG - 
C. parapsilosis AG - - - 
C. krusei AG - - - 
C. glabrata AG - - - 
C.guilliermondi  AG - AG - 
C. lusitaniae AG AG - - 
A: acid production; G: gas production 
e) Sugar assimilation test[32,33,35] – The test organism was sub-cultured on non-
nutrient agar. 4-5 colonies of the yeast were emulsified in 2 ml of normal saline. To 
the yeast suspension, 15 ml of yeast nitrogen agar base was added and mixed well and 
allowed to set at room temperature in petri-plate. Carbohydrate discs -glucose, maltose, 
sucrose, lactose, cellibiose, galactose, trehalose, raffinose, xylose, inositol and dulcitol 
were placed on the agar and incubated for 24-48 hours at 25°C. The assimilation of the 
particular carbohydrate by the yeast is indicated by the growth around the discs. The 
pattern of assimilation was noted. 
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Table 4: Carbohydrate Assimilation 
Speci
es 
Candida 
albicans 
C. 
dublinensis 
C. 
tropicalis 
C. 
parapsilos
is 
C. 
krusei 
C. 
kefyr 
C. 
guille
rmon
di 
C. 
glab
rata Carbo
hydrat
es 
Glu + + + + + + + + 
Mal + + + + - - + - 
Suc V V + + - + + - 
Lac - - - - - + - - 
Cel - - + - - + + - 
Gal + + + + - + + - 
Tre + - + + - - + + 
Raff - - - - - + + - 
Xyl + - + + - + + - 
Ino - - - - - - - - 
Dul - - - - - - + - 
+ positive, - negative, V variable 
ANTIMICROBIAL SUSCEPTIBILITY TEST 
A. ANTIBACTERIAL SENSITIVITY TEST 
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Kirby-Bauer disc diffusion method was used for antimicrobial sensitivity test and 
MIC was done for drugs meropenem and vancomycin. 
1) Kirby Bauer Disk Difffusion Method[37] 
Preparation of inoculum and Application of discs:-  
1. With a sterile bacteriological loop, 3- 4 well isolated and identical colonies were 
emulsified in 3-4ml of sterile peptone water. 
2. They were incubated for two hours at 37ºC and the density of the suspension was 
matched to 0.5 McFarland standard.  
3. A sterile cotton-wool swab was dipped into the suspension within 15 minutes 
and excess removed by rotating the swab against the side of the test tube.  
4. It was streaked evenly on to the entire surface of the Mueller Hinton Agar plate. 
Streaking was done in three different directions, rotating the plate approximately 
60°C to obtain a lawn culture and ensure even distribution.  
5. The inoculated plate was allowed to dry for 3 to 5 minutes and the antibiotic 
discs were placed, maximum of six on each plate. 
6. With each batch of tests, control strains were included as per the CLSI 
guidelines. 
Reading the sensitivity pattern:  
After 16-18 hours of incubation at 37°C, the diameter of zones of inhibition were 
measured in mm (as judged by the unaided eye), including the diameter of the disk.  
Panel of drugs were used for antimicrobial sensitivity testing: 
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Table 5: Gram negative bacilli (Enterobacteriaceae, Pseudomonas) 
Anibiotics 
 
Disc 
content 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
Ampicillin *# 10 µg ≥17 14-16 ≤13 
Amikacin 30 µg ≥17 15-16 ≤14 
Gentamicin 10 µg ≥15 13-14 ≤12 
Norfloxacin 10 µg ≥17 13-16 ≤12 
Nitrofurantoin# 300 µg ≥17 13-16 ≤14 
Trimethoprim- 
sulfamethoxazole 
(Cotrimoxazole) # 
1.25/ 
23.75 µg 
≥16 11-15 ≤10 
Cefotaxime# 30 µg ≥26 23-25 ≤22 
Ceftazidime 
   Enterobacteriaceae 
30 µg ≥21 16-20 ≤17 
  Pseudomonas 
aeruginosa 
≥18 15-17 ≤14 
Tetracycline# 30 µg ≥15 12-14 ≤11 
Piperacillin- Tazobactam 
   Enterobacteriaceae 
100/10 µg ≥21 18-20 ≤17 
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  Pseudomonas 
aeruginosa 
≥21 15-20 ≤14 
Imipenem 
   Enterobacteriaceae 
10 µg ≥23 20-22 ≤19 
  Pseudomonas 
aeruginosa 
≥19 16-18 ≤15 
Meropenem 
   Enterobacteriaceae 
10 µg ≥23 20-22 ≤19 
  Pseudomonas 
aeruginosa 
≥19 16-18 ≤15 
*: intrinsic resistance for Klebsiella pneumonia 
#: intrinsic resistance for Pseudomonas aeruginosa 
Table 6: Staphylococcus aureus 
Anibiotics 
 
Disc 
content 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
Penicillin 10 units ≥29 - ≤28 
Amikacin 30 µg ≥17 15-16 ≤14 
Gentamicin 10 µg ≥15 13-14 ≤12 
Norfloxacin 10 µg ≥17 13-16 ≤12 
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Nitrofurantoin 300 µg ≥17 13-16 ≤14 
Trimethoprim- 
sulfamethoxazole 
(Cotrimoxazole) 
1.25/ 23.75 
µg 
≥16 11-15 ≤10 
Cefoxitin  30 µg ≥22 - ≤21 
Tetracycline 30 µg ≥19 15-18 ≤14 
Table 7: Enterococcus spp. 
Anibiotics 
 
Disc content Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
Penicillin 10 units ≥15  - ≤14 
Tetracycline 30 µg ≥19 15-18 ≤14 
Norfloxacin 10 µg ≥17 13-16 ≤12 
Nitrofurantoin 300 µg ≥17 15-16 ≤14 
Vancomycin 30 µg ≥17 15-16 ≤14 
High level 
gentamicin 
120 µg ≥10 7-9 ≤6 
2) Minimum inhibitory concentration (MIC) 
a. MIC for Meropenem by macrobroth dilution method: [38] 
MIC was determined for the isolates that showed resistance to meropenem by disc 
diffusion method 
 Culture media: Cation adjusted Mueller Hinton broth (pH 7.2-7.4) 
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 Antibiotic stock solution: It was prepared using the formula:  
W  = 1000 x V x C                                     
                                  P 
where P= potency of the antibiotic in relation to the base. (For Meropenem, P= 
675/1000 µg) 
           V = volume of the stock solution to be prepared (10ml) 
           C = final concentration of the antibiotic solution (1024μg/ml) 
           W = weight of the antibiotic to be dissolved in the volume V 
15.17mg of drug was mixed with 10 ml of distilled water which contains 1024g/ml 
concentration of drug 
 Preparation of drug dilutions: 
                A row of 15 sterile test tubes were arranged (one row for each isolate). One 
ml of MH broth was added to each tube upto 14th tube. From the stock solution (tube 1) 
1ml was transferred to the second tube, then from the second to the third tube. This 
procedure was repeated till the thirteenth tube. One tube with only the antibiotic solution 
was kept as drug control. 
 Inoculum preparation for the test and ATCC control  
                  9.9 ml of MH broth was taken in a sterile test tube. 0.1ml of 0.5 Mc Farland 
turbidity matched test isolate suspension was added to it and mixed well. From this 1 
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ml of inoculum was transferred to each tube containing antibiotic dilutions. One tube 
containing only inoculum was kept as growth control also to the control tube.  
Same procedure was repeated for ATCC control strain and incubated overnight 
at 37ºC.  
 Interpretation- The lowest concentration of the antibiotic which showed 
clearing (no visible growth) was considered as the MIC for the ATCC strain & for the 
test organisms.  
 MIC of meropenem: 
≤2 µg/ml: susceptible 
4 µg/ml: intermediate 
≥8 µg/ml: resistant 
b. MIC for Vancomycin by macrobroth dilution method: [37,38] 
 Procedure- MIC for vancomycin was done in a similar way as for meropenem. 
However, the potency of vancomycin was taken as P= 950/1000 µg. 
Table 8: MIC range for Vancomycin 
Vancomycin Resistant 
µg/ml 
Intermediate 
µg/ml 
Sensitive 
µg/ml 
S.aureus ≥16 4-8 ≤2 
Enterococcus spp ≥32 8-16 ≤4 
c. MIC for vancomycin using Epsilometer test: [39] 
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In this method, MIC determination paper strip is used which is coated with 
vancomycin in a concentration gradient manner. It can show MIC’s in the range of 
0.016µg/ml to 256µg/ml on testing against the test organism. 
 Procedure- A lawn culture of the test isolate was done on MHA. The E-strip 
was placed on the agar surface and the plate incubated at 37°C for 16-24 hours. 
 Interpretation- MIC is read where the ellipse intersects the MIC scale on the 
strip. Isolated colonies, microcolonies and hazes appearing in the zone of inhibition 
indicates heteronature of the culture having resistant sub-population in it. In such cases, 
MIC is read at a point on the scale above which no resistant colonies are observed close 
to MIC strip. The range for MIC is same as that for macrobroth dilution method. 
3) Detection of extended spectrum betalactamase (ESBL)[37] 
Screening of possible ESBL production was done by using cefotaxime 
(30μg) and ceftazidime (30μg) discs. Those isolates with zone diameters ≤ 27mm for 
ceftriaxone and ≤22 mm for ceftazidime were subsequently confirmed for ESBL 
production. Confirmation was done by ESBL phenotypic confirmatory test. A lawn 
culture of the test organism was done and ceftazidime (30μg) alone and ceftazidime 
plus clavulanic acid(30/10μg) discs were placed with centres 30mm apart. An increase 
of ≥ 5mm in zone of inhibition of the combination discs in comparison to the 
ceftazidime disc alone was considered to be ESBL producer.  
4) Detection of Amp C beta-lactamases [40,41,60] 
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Screening for Amp C beta-lactamase was done using cefoxitin(30µg) disc. A zone 
diameter of ≤18mm was suspected as Amp C betalactamase producer. Such isolates 
were further confirmed by Amp C disc test. 
A lawn culture of ATCC E.coli 25922 strain was streaked on an MHA plate. The 
inoculum was allowed to dry and a cefoxitin disc (30μg) was placed at the centre of the 
plate. A sterile disc almost touching to the cefoxitin disc was placed. It was moistened 
with 20 μl of sterile saline and then inoculated with 3-4 colonies of the test organism. 
The plate was incubated overnight at 37°C. A flattening or inhibition of the cefoxitin 
inhibition zone in the vicinity of the disc was considered a positive result 
5) Detection of metallobetalactamase (MBL) [40,41,60] 
 Screening for MBL detection was done using imipenem (10μg) disc. Those isolates 
found resistant to imipenem were confirmed by imipenem EDTA combined disk test 
(33). A lawn culture of the test isolate was done and the discs were placed with centres 
30mm apart. A zone diameter difference of ≥ 7 mm between the imipenem and 
imipenem + EDTA (10/750μg) was interpreted as a positive result for MBL production. 
6) Detection of carbapenemase resistance [37,41] 
Those isolates which showed intermediate or resistant to one or more 
carbapenems (imipenem/meropenem) were tested for carbapenemase production by 
Modified Hodge test (MHT). A 0.5 McFarland suspension of E.coli ATCC strain was 
made in saline. It was diluted 1:10 in saline and then streaked on MH plate to produce 
a lawn culture. It was allowed to dry for 3-5 minutes and a meropenem disc (10 μg) was 
placed at the centre of the plate. Using a 10μl loop, 3-5 colonies of the test organism 
was picked up and inoculated in a straight line out from the edge of the disk. The streak 
45 
 
line should be at least 20-25mm in length. Control strain was also streaked. Up to 4 
organisms can be tested on the same plate. The plate was incubated overnight for 16-24 
hours at 37°C. A clover leaf-like indentation of the E.coli ATCC 25922 strain within 
the zone of inhibition of the carbapenem susceptibility was considered as positive MHT. 
7) Detection of methicillin resistance Staphylococcus aureus (MRSA) [37] 
A lawn culture of the test isolate was done and a cefoxitin disc (30µg) was 
placed. The plate was incubated overnight at 33-35°C. A zone of inhibition ≤21mm was 
taken as mec-A positive and considered as MRSA. 
B) ANTIFUNGAL SUSCEPTIBILITY  
1) Disc diffusion method[42] 
              Inoculum was prepared by suspending 4-5 colonies from 24 hour old culture 
grown on Sabouraud Dextrose Agar in 5 ml sterile saline (0.85%NaCl). The turbidity 
was adjusted to 0.5 McFarland standard.  
           Within fifteen minutes of suspension preparation, a sterile cotton-wool swab was 
dipped into it. The soaked swab was rotated against the upper inside wall of the tube to 
express excess fluid.  Mueller Hinton agar supplemented with 2% glucose and 0.5 µg/ml 
methylene blue plate was inoculated by streaking the entire surface of the plate with the 
swab three times, turning the plate at 60° angle between each set of streaking.  
                The inoculum was allowed to dry for 5-15 minutes and then the discs were 
placed with centres at least 24mm apart. The control strain C.albicans ATCC 90028    
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was also put up.  Antifungal discs used were Fluconazole (25µg) and Voriconazole (1 
µg) 
Table 9: Interpretative criteria for antifungal susceptibility 
Antifungal drug Disc potency Zone diameter range 
R SDD S 
Fluconazole* 25µg ≤14 15-18 ≥19 
Voriconazole 1µg ≤13 14-16 ≥17 
*: Intrinsic resistance for C.krusei 
2) Minimum inhibitory concentration (MIC) by microbroth dilution method [43]  
 Preparation of inoculum  
To obtain pure and viable cultures, the yeast isolates to be tested were 
subcultured on SDA. 4-5 colonies of 24 hour old culture was suspended in 5 ml sterile 
NaCl [0.85 %], vortexed for 15 seconds and the turbidity was adjusted to 0.5 McFarland 
standard. It was diluted 1:500 using RPMI-1640 medium i.e. 100 µl of yeast suspemsion 
is added to 5ml of RPMI1640 medium. 
 Weight of antifungal drugs 
Weight (mg) = volume(ml) x concentration ( µg/ml) 
                           Assay potency (µg/mg) 
 Preparation of stock solution 
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All drugs are dissolved in 10 ml of DMSO to prepare the stock solution of the drug. 
Water soluble drug, fluconazole was dissolved in the concentration of 5120 µg/ml and 
water insoluble drugs like itraconazole and amphotericin B were dissolved in the 
concentration of 1600 µg/ml. 
 Preparation of drug dilutions 
 Intermediate drug concentration 
Water soluble drugs- Ten tubes were arranged in a row. RPMI was added in the 
following manner: 7ml to the first tube, 1ml to second, fourth, seventh and tenth tubes;  
3 ml to the third tube; 1.5 ml to the fifth and eighth tubes and 3.5 ml to the sixth and 
ninth tubes.  
The drug was added in the following manner: From the stock solution, 1ml of 
drug was added to the first tube. From the first tube 1 ml was transferred to second and 
third tubes. From the third tube, 1 ml was transferred to the fourth tube and 0.5 ml to 
the fifth and sixth tubes. From the sixth tube 1 ml was transferred to seventh tube and 
0.5 ml to the eighth and ninth tube and from the ninth tube 1ml was transferred to tenth 
tube. 
Water insoluble drugs- Ten tubes were arranged in a row. Stock solution 1600 µg was 
taken in first tube. DMSO was added in the following manner: 0.5 ml to the second, 
fifth and eighth tubes; 1.5 ml to the third, sixth and ninth tubes and 3.5 ml to fourth, 
seven and tenth tubes. 
48 
 
The drug was added in the following manner: 0.5 ml of the drug was transferred 
from the 1st tube to 2nd, 3rd and 4th tubes; 0.5 ml from the 4th tube to 5th, 6th and 7th tubes 
and 0.5 ml from 7th tube to 8th, 9th and 10th tubes. 
 Final drug concentration 
Water soluble drug- Another row of ten test tubes were arranged and 4 ml of RPMI 
was added to all the tubes. 1ml of intermediate drug concentration prepared were added 
to these tubes from the corresponding rows. 
Water insoluble drug- Another row of ten test tubes are arranged. 4.9 ml of RPMI was 
added to all the tubes. 0.1ml of intermediate drug concentration prepared were added to 
these from the corresponding rows. 
Table 10: Preparation of dilutions of water soluble antifungal drug 
Tube 1 2 3 4 5 6 7 8 9 10 
Source: From 
stock 
From 
tube 1 
From 
tube 
1 
From 
tube 
3 
From 
tube 
3 
From 
tube 
3 
From 
tube 
6 
From 
tube 
6 
From 
tube 
6 
From 
tube 
9 
Add 
drug 
(ml) 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
0.5 
+ 
0.5 
+ 
1.0 
+ 
0.5 
+ 
0.5 
+ 
1.0 
+ 
Add 
solvent 
7.0 1.0 3.0 1.0 1. 5 3. 5 1. 0 1.5 3.5 1.0 
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RPMI 
(ml) 
Interme
diate 
drug 
concent
ration 
(row 1) 
640 320 160 80 40 20 10 5 2.5 1.25 
Add 
drug 
from 
tube in 
row 1 
above 
(ml) 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
1.0 
+ 
Add 
RPMI 
1640 
(ml) 
4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
Final 
concent
ration 
(µg/ml) 
64 32 16 8 4 2 1 0.5 0.25 0.125 
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Table 11: Preparation of  dilutions of water soluble antifungal drug 
Tube 1 2 3 4 5 6 7 8 9 10 
Source
: 
Stock From 
tube 
1 
From 
tube 
1 
From 
tube 
3 
From 
tube 
3 
From 
tube 
3 
From 
tube 
6 
From 
tube 
6 
From 
tube 6 
From 
tube 9 
Add 
drug 
(ml) 
- 0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
0.5 
+ 
Add 
solvent 
DMSO 
(ml) 
- 0.5 1.5 3.5 0.5 1.5 3.5 0.5 1.5 3.5 
Inter
mediat
e drug 
concen
tration 
1600 800 400 200 100 50 25 12.5 6.25 3.13 
Add 
drug 
from 
tube in 
row 1 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
0.1 
+ 
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above 
(ml) 
Add 
RPMI 
1640 
(ml) 
4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 4.9 
Final 
concen
tration 
(µg/ml
) 
16 8 4 2 1 0.5 0.25 0.125 0.0625 0.0313 
 Inoculation of the plate and incubation 
A sterile flat bottomed 96 well microtitre plate was labelled. Wells 1 to 10 were 
labelled for drug concentrations: 64 to 0.125 for water soluble drug i.e. fluconazole and 
16 to 0.0313 for water insoluble drugs i.e. itraconazole and amphotericin B; 11th well 
for growth control and 12th well for drug control. 100µl of each serial dilution of 
antifungal agents were added in the respective wells. 100µl of the inoculum was added 
to wells 1 to 10. To the 11th well, 100µl of RPMI and 100µl of the inoculum was added. 
To the 12th well, 100µl 0f RPMI and 100µl of drug from stock solution were added.  
The microtitre plate was incubated at 35º C for 48 hours. 
 Observation  
Reading of results and scores:  
1- Optically clear  
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2- Approximately 25% of the growth control or Slighty hazy 
3- Approximately 50% of the growth control or prominent decrease in turbidity 
4- Approximately as of the growth medium or slight reduction in turbidity 
5- No reduction in turbidity 
 Interpretation 
The MIC for the drugs was the lowest concentration with a score of 3 for water soluble 
drugs and score of 1 for amphotericin B 
Table-12: MIC range for Azole drugs by microbroth dilution method 
Candida spp Resistant 
µg/ml 
Susceptible dose 
dependent             µg/ml 
Sensitive 
µg/ml 
Fluconazole  ≥64 16-32 ≤8 
Itraconazole ≥1 0.25-0.5 0.125 
Amphotericin B >1 - ≤1 
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RESULTS 
STATISTICAL ANALYSIS: 
Occurrence of symptomatic CAUTI was taken as primary outcome. Various 
personal (age, gender, etc) and clinical parameters (type of disease, steroid use, etc) of 
the patients were considered as explanatory factors. Descriptive analysis of all the 
explanatory and outcome parameters was presented as frequencies and percentages. The 
association between explanatory and outcome variables was analyzed by calculating 
odds ratios and their 95% confidence intervals. Statistical significance of this 
association was analyzed using chi square test. Microsoft excel and IBM SPSS version 
21 were used for analysis. 
RESULTS: 
In this study, total of 100 patients were enrolled and included in the final analysis.  
Table 13: Incidence of symptomatic CAUTI  
Total Number of cases with Symptomatic CAUTI 26 (26%) 
Total Duration of catheterisation (days) 1013 
 Symptomatic CAUTI rate per 1000 catheter days 26/1013*1000=25.67 
 
The incidence rate of CAUTI per 1000 catheter days was calculated as 25.67 cases in 
the study population. 
 
Table 14: Descriptive analysis of age-wise distribution in study group (N=100) 
54 
 
Age Groups Frequency Percent 
18 to 30 yrs 33 33.0 
31 to 40 yrs 24 24.0 
41 to  50 yrs 18 18.0 
51 to  60 yrs 11 11.0 
61 to 70 yrs 10 10.0 
71 to 80 yrs 4 4.0 
  
The age distribution of the participants showed, maximum proportion (33%) of 
subjects belonging to 18 to 30 years. The proportion of subjects with age between 31 to 
40 years, 41 to 50 yrs, 51 to 60 years, 61 to 70 yrs and 71 to 80 yrs was 24%, 18%, 11% 
10 and 4% respectively.  
Fig 4: Pie chart of age groups distribution in study group (N=100) 
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71 to 80 yrs
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Table 15: Descriptive analysis of gender distribution in study group (N=100) 
Gender Frequency Percent 
Male 57 57.0 
Female 43 43.0 
 
Males constituted 57% and females contributed 43% of study subjects. 
Fig 5: Bar chart of gender distribution in study group (N=100)
 
Table 16: Descriptive analysis of Total catheter days in study group (N=100) 
Total catheter days Frequency Percent 
1 to 7 Days 11 11.0 
8 to 14 days 85 85.0 
15 to 21 days 4 4.0 
Total 100 100.0 
 
In majority of Patients total catheter days were in the range of 8 to 14 days (85%).In 1 
to 7 days range 11 (11%) and in 15 to 21 days only 4(4%) patients were there.  
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Fig 6: Pie chart of total catheter days distribution in study group (N=100)
 
Table 17: Descriptive analysis of Indication for catheterisation and validity in 
study group (N=100) 
Parameter Frequency Percent 
I. Indication for catheterisation 
Monitor urinary output 96 96.0 
Monitor urinary output, relieve 
urinary retention 
4 4.0 
II. Indication valid 
Yes 100 100.0 
No 0 0.0 
 
 The indication for catheterisation was valid for all cases 
11%
85%
4%
1 to 7 Days
8 to 14 days
15 to 21 days
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Fig 7: Bar chart of indication for catheterisation distribution in study group 
(N=100)
 
Table 18: Descriptive analysis of CAUTI parameters in study group (N=100)  
Parameter Frequency Percent 
I. Symptomatic CAUTI 
Yes 26 26.0 
No 74 74.0 
II. Day of development of Symptomatic CAUTI (N=26) 
10 4 15.3 
14 19 73.0 
21 3 11.5 
  
A total of 26 (26%) of subjects developed symptomatic CAUTI during the hospital stay. 
Out of symptomatic CAUTI, majority 19 (73%) developed it on 14th day, followed by 
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4(15.3%), who developed on day 10. Remaining 3(11.5%) subjects developed CAUTI 
on 21st day.  
Fig 8: Bar chart of Symptomatic CAUTI distribution in study group (N=100) 
 
Fig 9: Pie chart of day of development of Symptomatic CAUTI distribution in 
study group (N=26) 
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Table 19: Descriptive analysis of day of development of symptomatic CAUTI in 
study group (N=100)  
Parameter Frequency Percent 
I.@3 days 
Yes 0 0.0 
No 100 100.0 
II. @5 days 
Yes 0 0.0 
No 100 100.0 
III. @ 7 days 
Yes 0 0.0 
No 100 100.0 
IV.@ 10 days (N=63) 
Yes 4 6.3 
No 59 93.6 
V. @ 14 days  (N=22) 
Yes 19 86.3 
No 3 13.6 
VII. @21 days (N=4)   
Yes 3 75.0 
No 1 25.0 
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Table 20: Descriptive analysis of Risk factors in study group (N=100) 
Parameter Frequency Percent 
I. Age 50yrs and above 
Yes 26 26.0 
No 74 74.0 
III. Duration of catheterisation ≥10days 
Yes 43 43.0 
No 57 57.0 
IV. Diabetes mellitus 
Yes 17 17.0 
No 83 83.0 
V. Neurological causes 
Yes 18 18.0 
No 82 82.0 
VI. Respiratory causes  
Yes 11 11.0 
No 89 89.0 
VII. Urological Nephrological causes 
Yes 5 5.0 
No 95 95.0 
VIII. Steroid 
Yes 5 5.0 
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No 95 95.0 
IX. Other immunocompromised conditions 
Yes 5 5.0 
No 95 95.0 
X. Faulty catheter care 
Yes 3 3.0 
No 97 97.0 
 
The descriptive analysis of all the potential risk factors for development of symptomatic 
CAUTI is presented in table 7. A total of 26(26%) of participants were aged above 50 
years. The proportion of subjects who had catheterization for more than 10 days was 
43% .17 % of subjects had Diabetes mellitus. The proportion of subjects, who were 
suffering from neurological, respiratory conditions, was 18% and 11% respectively. 
Only 5% of subjects were suffering from urological/nephrological conditions and 5 
patients each had steroid use and other immunocompromised conditions. 3 patients each 
had faulty catheter care. 
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Fig 10:Bar chart of Risk factors distribution in study group
 
Table 21: Association between Age groups and CAUTI in study group (N=100) 
Parameter Symptomatic 
CAUTI 
 Chi square value P value 
  Yes No     
Age groups         
18 to 30 yrs 
5 28     
15.15% 84.85%     
31 to 40 yrs 5 19 10.722 0.057 
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20.83% 79.17%     
41 to  50 yrs 
8 10     
44.44% 55.56%     
51 to 60 yrs 
3 
27.3% 
8 
72.7% 
  
  
61 to 70 yrs 
2 
20.0% 
8 
80.0% 
  
  
71 to 80 yrs 
3 
75.0% 
1 
25.0% 
  
  
 
The occurrence of CAUTI was found highest in age group 71-80 years. However, the 
association was not statistically significant between the age groups and occurrence of 
CAUTI in the study population. 
Table 22: Patient personal and clinical factors influencing in study group (N=100) 
Parameter Symptomatic 
CAUTI 
Odds 
ratio 
Chi square 
value 
P value 95% CI 
Yes No Lower Upper 
1.Age 50yrs and above  
Yes 8 18   
1.383 
  
  
  
0.415 
  
  
  
0.519 
  
  
  
0.515 
  
  
  
3.713 
  
  
  30.77% 69.23% 
No 18 56 
  24.32% 75.68% 
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II. Gender  
Female 15 28   
2.240 
  
  
  
3.094 
  
  
  
0.079 
  
  
  
0.903 
  
  
  
5.559 
  
  
  34.88% 65.12% 
Male 11 46 
  19.30% 80.70% 
III.Duration of catheterisation ≥10days 
Yes 26 17 
- 46.574 0.000 0.273 0.572 
  60.47% 39.53% 
No 0 57 
  0.00% 100.00% 
VIII. Steroid use 
Yes 2 3   
1.972 
  
  
0.536 
  
  
  
0.464 
  
  
  
0.311 
  
  
  
12.519 
  
  
  40.00% 60.00% 
No 24 71 
  25.26% 74.74% 
X. Faulty catheter care 
Yes 1 2  
 
1.440 
 
 
0.086 
 
0.769 
 
 
0.125 
 
 
16.574 
 33.3% 66.7% 
No 25 72 
 25.8% 74.2% 
 
The odds of occurrence of symptomatic CAUTI were 1.38 times in people above 50 
years, compared with people below 50 years, which was statistically not significant. (P 
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value 0.5, 95% CI 0.51 to 3.71). Female gender had 2.2 times higher risk of developing 
CAUTI, compared to males (p value 0.07, 95 CI 0.90 to 5.55). None of the patients 
catheterized for less than 10 days had CAUTI. The patients who were on steroids had 
1.97 times more risk of developing UTI, compared to other people (P value0.464, 95% 
CI 0.311 to 12.519).  The patients with faulty catheter care had 1.440 times risk of 
developing CAUTI. However it was not statistically significant (P value 0.769, 95% CI 
0.125. to 16.574) 
Table 23: Association between morbidity and symptomatic CAUTI in study group 
(N=100) 
Parameter Symptomatic 
CAUTI 
Odds 
ratio 
Chi 
square 
value 
P 
value 
95% CI 
Yes No Lower Upper 
IV. Diabetes Mellitus 
Yes 10 7   
5.982 
  
  
  
11.469 
  
  
  
0.001 
  
  
  
1.973 
  
  
  
18.138 
  
  
  58.82% 41.18% 
No 16 67 
  19.28% 80.72% 
V. Neurological causes 
Yes 10 8   
5.156 
  
  
  
9.966 
  
  
  
0.002 
  
  
  
1.754 
  
  
  
15.157 
  
  
  55.56% 44.44% 
No 16 66 
  19.51% 80.49% 
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VI. Respiratory causes 
Yes 7 4 
6.447 9.099 0.003 1.707 24.353 
  63.6% 36.4% 
No 19 70 
  21.35% 78.65% 
VII. Urological Nephrological causes 
Yes 4 
80.00% 
1 
20.00% 
  
13.273 
  
  
  
7.977 
  
  
  
0.005 
  
  
  
1.409 
  
  
  
124.994 
  
  
No 22 
23.16% 
73 
76.84% 
IX. Other immunocompromised conditions 
Yes 2 3 
1.972 0.536 0.464 0.311 12.519 
  40.00% 60.00% 
No 24 71 
 25.26% 74.74% 
 
The odds of symptomatic CAUTI were 5.98 times more in diabetic people (P value 
<0.001, 95 CI 1.97 to 18.13). People suffering from neurological and respiratory 
diseases had 5.16 (p value 0.002, 95 CI 1.75 to 15.15) times and 6.44 (P value 0.003, 
95% CI 1.70 to 24.35) times more risk of symptomatic CAUTI. People with 
urological/nephrological condition had the highest risk of suffering from symptomatic 
CAUTI, with an odds ratio of 13.27 (P value 0.003, 95% CI 1.4 to 124.99). The persons 
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with other immunocompromised conditions had no statistically significant increased 
risk of CAUTI.  
Table 24: Descriptive analysis of Organism isolated in study group (N=40) 
 
Organism Isolated 
Frequency Percent 
Candida Species 6 15.0 
Gram negative bacilli 
      Enterobacteriaceae 14 34.5 
      Non-fermenters 13 32.5 
Gram positive organisms 7 17.5 
Total 40 100.0 
 
Majority of the organisms isolated belonged to Enterobacteriaceae (34.5%) and non-
fermenters (32.5%). Candida species (15.0%) and Gram positive organisms (17.5%) 
contributed to the remaining portion of the organisms. 
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Fig 11: Pie chart organism isolated distribution in study group (N=100)
 
Table 25: Descriptive analysis of Organism isolated in study group (N=40) 
 
Organism Isolated 
Frequency Percent 
Candida  species 6 15 
Enterobacteriaceae 
       Escherichia coli 6 15.0 
       Klebsiella oxytoca 1 2.5 
       Klebsiella pneumoniae 7 17.5 
Non-fermenters 
      Pseudomonas aeruginosa 10 25.0 
      Pseudomonas stutzeri 2 5.0 
      Pseudomonas fluorescens 1 2.5 
Gram Positive organisms 
15%
35%32%
18%
Candida Species
Enterobacteriaceae
Non fermenters
Gram positive
organisms
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Staphylococcus aureus 1 2.5 
Enterococcus faecalis 6 15.0 
Total 40 100.0 
 
Fig 12: Pie chart for distribution of organisms isolated in study group (N=100)
 
Pseudomonas aeruginosa was the most common isolate (25%) followed by Klebsiella 
pneumoniae (17.5%), Enterococcus faecalis (15%), Escherichia coli (15%) and 
Candida spp. (15%). Other isolates were Pseudomonas stutzeri (5%), Klebsiella 
oxytoca (2.5%), Pseudomonas fluorescence (2.5%). and Staphylococcus aureus (2.5%). 
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Table 26: Descriptive analysis of Candida spp. isolated in study group (N=6) 
 
Organism Isolated 
Frequency Percent 
Candida albicans 1 16.7 
Non-albicans Candida  5 83.3 
Total 6 100.0 
 
Fig 13: Bar chart organism isolated distribution in study group (N=100)
 
Among the candida species, non-albicans Candida spp. contributed to 83.3% of the 
isolates and only 16.7% of isolates were Candida albicans 
Table 27: Descriptive analysis of various species of Candida isolated in study group 
(N=6) 
Candida species Frequency Percentage 
      Candida albicans 1 16.67 
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      C.tropicalis 2 33.33 
      C.krusei 1 16.67 
      C.parapsilosis 1 16.67 
      C.glabrata 1 16.67 
 
Fig 14: Pie chart of Candida species isolated distribution in study group (N=6)
 
 
Among non-albicans Candida, 2 patients had Candida tropicalis and one patient each 
had Candida krusei, Candida parapsilosis and Candida glabrata isolate. 
Table 28:Descriptive analysis of antimicrobial sensitivity pattern for 
Enterobacteriaceae in study group (N=14) 
Drug 
Escherichia coli 
(n=6) 
Klebsiella 
oxytoca (n=1) 
Klebsiella 
pneumoniae 
(n=7) 
16%
33%
17%
17%
17%
      Candida albicans
      C.tropicalis
      C.krusei
      C.parapsilosis
      C.glabrata
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 Ampicillin 0 (0%) 0 (0%) * 
 Amikacin 0 (0%) 0 (0%) 0 (0%) 
 Gentamicin 1 (16.7%) 0 (0%) 0 (0%) 
 Nitrofurantoin 3 (50%) 1 (100%) 1 (14.3%) 
 Norfloxacin 0 (0%) 0 (0%) 1 (14.3%) 
 Cotrimoxazole 0 (0%) 0 (0%) 0 (0%) 
 Cefotaxime 0 (0%) 0 (0%) 0 (0%) 
 Ceftazidime 0 (0%) 0 (0%) 0 (0%) 
 Piperacilin-
tazobactam 5 (83.3%) 
1 (100%) 3 (42.9%) 
 Imipenem 6 (100.0%) 1 (100%) 5 (71.4%) 
 Meropenem 6 (100%) 1 (100%) 5 (71.4%) 
 Tetracycline 0 (0%) 0 (0%) 1 (14.3%) 
*: intrinsic resistance 
There was a high degree of resistance observed among Enterobacteriaceae. However, 
they were commonly sensitive to piperacillin-tazobactam, imipenem and meropenem. 
Table 29: Descriptive analysis of antimicrobial sensitivity pattern for Non-
fermenters in study group (N=13) 
Drug 
Pseudomonas 
aeruginosa (n=10) 
N(%) 
Pseudomonas 
stutzeri (n=2) 
N(%) 
Pseudomonas 
fluorescens (n=1) 
N(%) 
 Amikacin 1 (10%) 0 (0%) 0 (0%) 
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 Gentamicin 1 (10%) 0 (0%) 0 (0%) 
 Norfloxacin 2 (20%) 0 (0%) 0 (0%) 
 Cotrimoxazole * 
0 (0%) 0 (0%) 
 Cefotaxime * 
0 (0%) 0 (0%) 
 Ceftazidime 1 (10%) 0 (0%) 0 (0%) 
 Piperacilin-
tazobactam 7 (70%) 
1 (50%) 1 (100%) 
 Imipenem 9 (90%) 2 (100%) 1 (100%) 
 Meropenem 9 (90%) 2 (100%) 1 (100%) 
 Tetracycline * 0 (0%) 0 (0%) 
*: intrinsic resistance 
Among Pseudomonas aeruginosa isolates, majority of them were sensitive to Imipenem 
(90%), meropenem (90%) and Piperacilin-tazobactam (70%). Among Pseudomonas 
stutzeri and P.fluorescens isolates, all the isolates were sensitive to imipenem and 
meropenem. Only 50% of Pseudomonas stutzeri were sensitive to Piperacilin-
tazobactam. 
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Table 30:Descriptive analysis of antimicrobial sensitivity pattern for Enterococcus 
species in study group (N=6) 
Drug 
 
Sensitive 
N (%) 
Nitrofurantoin 4 (66.7%) 
Norfloxacin 3 (50.0%) 
Tetracycline 1 (16.7%) 
Penicillin 0 (0.0%) 
Vancomycin 6 (100.0%) 
High level gentamicin 5 (83.3%) 
 
Among 6 isolates of Enterococcus species 100% were sensitive for vancomycin. The 
proportion of isolates sensitive for nitrofurantoin, norfloxacin, tetracycline and high 
level gentamicin was 66.7%, 50% , 16.7% and 83.3% respectively. None of the isolates 
were sensitive to penicillin. 
Table 31:  Descriptive analysis of drug sensitivity for Staphylococcus aureus in 
study group (N=1) 
Drug Sensitive, N (%) 
 Amikacin 0 (0.0%) 
 Gentamicin 0 (0.0%) 
 Nitrofurantoin 1 (100.0%) 
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 Norfloxacin 0 (0.0%) 
 Cotrimoxazole 0 (0.0%) 
 Cefoxitin 0 (0.0%) 
 Tetracycline 1 (100.0%) 
 Vancomycin 1 (100.0%) 
 Penicillin 0 (0.0%) 
Linezolid 1(100.0%) 
 
Staphylococcus aureus isolate was sensitive to nitrofurantoin, tetracycline, vancomycin 
and linezolid. 
 
Table 32:  Descriptive analysis of drug sensitivity for Candida spp. in study group 
(N=6) 
Drug 
 
Resistance 
N (%) 
Sensitive 
N (%) 
 Fluconazole* 0(0.0%) 5 (100.0%) 
 Voriconazole 0 ( 0.0%) 6 (100.0%) 
 Amphotericin B 0 ( 0.0%) 6 (100.0%) 
Itraconazole 0 ( 0.0%) 6 (100.0%) 
*: intrinsic resistance for C.krusei 
All the candida isolates were sensitive to fluconazole, voriconazole, amphotericin B and 
itraconazole.  
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Table 33: Descriptive analysis of antibiotic resistant pattern in organisms isolated  
Parameter Frequency Percent 
I. ESBL(n=27) 
Yes 18 66.67 
No 9 33.33 
Total 27 100 
II. Amp C (n=27) 
Yes 6 22.22 
No 21 77.78 
Total 27 100 
III. MBL (n=27) 
Yes 3 11.11 
No 24 88.89 
Total 27 100 
IV. Carbapenemase (n=27) 
Yes 3 11.11 
No 24 88.89 
Total 27 100 
V. MRSA(n=1) 
Yes 1 100 
No 0 0 
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Fig 15: Antimicrobial resistance pattern of the organisms isolated
 
Among 27 isolates of Gram negative bacilli, 66.67 % for ESBL, 22.22% Amp C, 11.11 
% MBL and 11.11% were positive for carbapenemase production. One Staphylococcus 
aureus was isolated which was methicillin resistant. 
Table 34: Descriptive analysis of Type of Symptomatic CAUTI in study group 
(N=26) 
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Mono microbial infection 12 46.15 
Poly  microbial infection 14 53.84 
Total 26 100.0 
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Fig 16: Bar chart of Symptomatic CAUTI distribution in study group (N=26)
 
Among the 26 cases of CAUTI, 12 (46.15%) were monomicrobial infections and 
remaining 14 (53.84%) were poly microbial infections. 
Table 35: Distribution of organisms in polymicrobial infections 
S.no. Organism 1 Organism 2 Frequency 
1 Escherichia coli Enterococcus faecalis 1 
2 Klebsiella pneumoniae Enterococcus faecalis 1 
3 Pseudomonas aeruginosa Candida krusei 1 
4 Candida albicans Enterococcus faecalis 1 
5 Klebsiella pneumonia Pseudomonas fluorescens 1 
6 Escherichia coli Candida parapsilosis 1 
7 Pseudomonas aeruginosa Candida tropicalis 2 
8 Klebsiella pneumonia Pseudomonas stutzeri 1 
9 Escherichia coli Klebsiella pneumonia 1 
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10 Pseudomonas aeruginosa Candida glabrata 1 
11 Klebsiella pneumoniae Pseudomonas aeruginosa 1 
12 Pseudomonas aeruginosa Escherichia coli 2 
 
Table 36: Distribution of organisms in monomicrobial infections 
S.no. Organism Frequency 
1. Escherichia coli 1 
2. Klebsiella pneumoniae 2 
3. Klebsiella oxytoca 1 
4. Pseudomonas aeruginosa 3 
5. Pseudomonas stutzeri 1 
6. Staphylococcus aureus 1 
7. Enterococcus faecalis 3 
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DISCUSSION 
Catheter associated urinary tract infection is the commonest device associated 
nosocomial infection. A total of 100 patients admitted in medical ICU were enrolled in 
the study and followed up for the development of CAUTI. In this study, only 
symptomatic cases were included under CAUTI. 
The rate of device associated infections shows variation in India. According to a 
study conducted by Angshuman Jana et al (2015) [44], the incidence was 31.85%. 
Another study by Neha Garg et al (2015) [45] found the incidence to be 20%. A study by 
Priya Datta et al (2014) [46] found the CAUTI rate as 10.75% and 9.08/1000 catheter 
days by Pooja et al (2014) [47] as 32.14%, by Kamat et al (2009) [48] as 33.6%, 
C.M.Poudel et al (2008) [8]  as 54% and Al Jebouri et al (2006) [49] as 28.1 %. Habibi et 
al (2008) [50] conducted a study in AIIMS, Delhi and reported CAUTI as 24% of 
nosocomial UTIs, the rate being 11.3/1000 catheter days. Study conducted in ICUs of 
four Mexican public hospitals reported CAUTI as 21.79% [51]. A survey conducted to 
determine the DAIs in the ICUs of 8 different developing countries reported that CAUTI 
comprised 29% of all DAIs (52). Due to these wide variations in the incidence, it is 
important for a hospital to generate its own data for the implementation on proper 
infection control programmes. 
In this study, out of 100 patients, 26 patients were diagnosed to develop 
symptomatic CAUTI during their course of hospitalisation. Therefore, the incidence 
was 26% and the CAUTI rate was calculated as 25.67 per 1000 catheter days.  
The age distribution of the study subjects showed maximum proportion (33%) 
of the patients belonged to 18-30 years. Males constituted 57% and females 43% of the 
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study subjects. In majority of the patients (85%), total catheter days were in the range 
of 8-14 days. The indication of catheterisation was found to be valid in all patients. 
Among 26 patients who developed symptomatic CAUTI, 19 developed in day 14. 
A number of risk factors implicated with the development of symptomatic 
CAUTI were studied .The p value and Odd’s ratio were calculated by Chi square test to 
find the statistical significance (p<0.05) and the strength of association of these risk 
factors. Age ≥ 50 years showed increased development of CAUTI, the risk being 1.38 
times. The incidence was also higher among females (34.88%) than males (19.3%). 
However, in this study age and gender showed no statistical significance. Similar results 
were seen in studies conducted by Priya et al [46], Meric et al [53] and Agrawal et al [54].  
Duration of catheterisation and length of hospital stay constitute an important 
risk factor and has been cited in studies by Priya Datta et al [46] and Angshuman Jana et 
al [44]. In this study, maximum patients (85%) belonged to the category of duration of 
catheterisation for 8 to 14 days. Among patients catheterised for 14 days, 86.3% 
developed CAUTI and among 4 patients catheterised till 21 days, 75% developed the 
infection. Duration of catheterisation 10 ≥days was found to be statistically significant 
as among 43 patients who had catheter for 10 ≥days, 60.47% developed CAUTI. This 
is due to the fact that the longer a patient stays in the ICU and catheterised, more are 
the chances that he will get colonised with multidrug resistant organisms present in the 
environmental niche. 
Faulty catheter care is another risk factor, but in this study it was not found to 
be statistically significant. 
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Co-morbidities have significant association with the development of CAUTI. In 
this study, diabetes had 5.98 times the risk, neurological causes 5.16 times, respiratory 
conditions such as COPD 6.44 times and those with urological/ nephrological causes 
had 13.27 times the risk. All these co-morbidities were statistically significant. These 
results are similar to study by Priya Datta et al [46] where diabetes and COPD had 
significant association. 
Infection by two organisms is common in CAUTI. In the study polymicrobial 
infection was seen in 53.84% and monomicrobial in 46.15 % of the cases. Total of 40 
organisms were isolated. 
In this study, the predominant isolates were Gram negative bacilli comprising 
67% of the isolates among which Enterobacteriaceae were 34.5% and non-fermenters 
32.5%. This finding was similar to other studies where in GNB constituted the common 
isolate: Neha Garg et al (80%) [45], Priya Datta et al (72.61%) [46] and C.M.Poudel et al 
(66.67%) [8]. 
The organisms causing CAUTI vary from one geographical area to another and 
there is changing trend over a period of time. A prospective study conducted by Tullu 
MS et al (1998) [55] found the commonest organism was Escherichia coli. Wazait et al 
(2003) [16] although reported similar result, noticed a declining trend over the period 
time. Enterococcus spp. was isolated as the second commonest organism. Another study 
by Taiwo et al (2006) [55] revealed multiresistant Klebsiella spp. as the commonest 
isolate followed by Pseudomonas spp., Escherichia coli, Staphylococcus aureus, 
Proteus mirabilis and coagulase negative staphylococci. A study by Priya Datta et al 
(2014) [46] found Pseudomonas aeruginosa (35.7%) as the commonest isolate followed 
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by Enterococcus spp.(15.4%) and Klebsiella pneumoniae (15.4%), Candida 
spp.(11.9%), Escherichia coli (10.7%), Acinetobacter spp (9.5%) and Morganella 
morganii (1.1%). Study by Neha Garg et al (2015) [45] found Escherichia coli as the 
commonest isolate(40%) followed by Citrobacter koseri (20%), Staphylococcus aureus 
(15%), Klebsiella oxytoca (10%), Acinetobacter spp (5%). Pseudomonas aeruginosa 
(5%) and Enterococcus faecalis (5%). According to a study by Angshuman Jana et al 
(2015) [44], the main pathogen belonged to Enterobacteriaceae among which 
Escherichia coli was 19.4%. Other organisms included Pseudomonas spp. 19.4% 
followed by Klebsiella spp. (16.6%), Staphylococcus and Candida spp.(11%) each. 
In the present study, Pseudomonas aeruginosa was the commonest isolate (25%) 
followed by Klebsiella pneumonia (17.5%), Escherichia coli, Enterococcus faecalis 
and Candida spp. (15%) each. P.stutzeri comprised 5% and Klebsiella oxytoca, 
P.fluorescens and Staphylococcus aureus 2.5% each. Among the gram positive bacteria, 
Enterococcus faecalis comprised 6 isolates and Staphylococcus aureus one isolate. 
There is an increasing trend of Enterococcus faecalis causing CAUTI. 
Among Candida isolates, non-albicans Candida spp. (83.3%) emerged as the 
predominant isolate. These included Candida tropicalis (2), C.parapsilosis (1), C.krusei 
(1) and C.galbrata (1). These findings were similar to the findings in a study conducted 
by Manisha Jain et al (2011) [57] where non-albicans Candida spp. (71.4%) was the 
predominant pathogen causing CAUTI. Similar results were seen in a study by Chanda 
R. Vyawahare et al (2015) [58]. Non-albicans Candida spp. are thus replacing Candida 
albicans as the predominant pathogen for nosocomial UTI. 
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 Different studies have shown high degree of antibiotic resistance among the 
pathogens causing CAUTI such as studies by Angshuman et al (2015) [44], Neha Garg 
et al(2015) [45], Priya Datta et al(2014) [46] and Chanda R. Vyawahare et al (2015) [58]. It 
is reported that catheterisation increases the prevalence of UTI caused by some highly 
resistant pathogens and the resistant pattern of the isolates changes from time to time.[16]. 
In the present study, among Enterobacteriaceae, the organisms were mostly resistant to 
ampicillin, amikacin, gentamicin, nitrofurantoin, norfloxacin, cotrimoxazole, 
tetracycline, cefotaxime and ceftazidime. For piperacillin-tazobactam, sensitivity was 
more – E.coli(83.3%), K.oxytoca (100%) and K.pneumoniae (42.9%). All isolates were 
uniformly sensitive to imipenem and meropenem except one isolate of K.pneumoniae 
which was resistant to carbapenems. Among non-fermenters, P.aeruginosa was 
predominantly sensitive to piperacillin-tazobactam, imipenem and meropenem. Among 
gram positive cocci, E.faecalis was 100% sensitive to vancomycin, 83.3% to high level 
gentamicin, 66.7% to nitrofurantoin and 50% to norfloxacin. Low level of sensitivity 
was seen for tetracycline (16.67%). One isolate of S.aureus was MRSA which was 
sensitive to nitrofurantoin, tetracycline, vancomycin and linezolid. 
 All the Candida spp. were uniformly sensitive to antifungals- fluconazole, 
itraconazole, voriconazole and amphotericin B. This may be due to the fact that the 
routine use for antifungal is not much. So, the organisms have not developed resistance. 
 Antimicrobial resistance is the main concern in healthcare associated infections 
because of the rapid increasing incidence. In this study, 66.67% of the GNB isolates 
were ESBL producers, 22.22% Amp C producers and 11.11% were positive for 
metallobetalactamase and carbapenemase each. This finding was similar to the study by 
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Mita et al (2013) [59]. In another study conducted by Neha Garg et al (2015) [45] , ESBL 
production was found in 25% of the strains, 37.5% of the isolates were positive for Amp 
C production and MBL was detected in 18.7% of the isolates.   
In the study, one Staphylococcus aureus isolated was MRSA and there was no 
vancomycin resistant enterococci. 
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SUMMARY 
• A total of 100 patients admitted in IMCU and put on Foley’s catheter were 
included in the study. 
• These patients were followed up for the development of symptomatic CAUTI. 
The urine samples from the catheter were collected on day 1 and then on day 
3,5,7,10,14 and every weekly till the patient was discharged, expired, catheter 
removed or developed bacteriuria. 
• Total 26 patients developed Symptomatic CAUTI, thereby the incidence being 
26 % and the CAUTI rate was calculated as 25.67 per 1000 catheter days.  
• The age distribution of the study subjects showed maximum proportion (33%) 
of the patients belonged to 18-30 years.  
• Males constituted 57% and females 43% of the study subjects. In majority of the 
patients (85%), total catheter days were in the range of 8-14 days.  
• The indication of catheterisation was found to be valid in all patients.  
• Among 26 patients who developed symptomatic CAUTI, 19 developed in day 
14. 
• Various risk factors associated with symptomatic CAUTI were studied. 
Statistically significant risk factors included duration of catheterisation ≥10 days 
and comorbid conditions such as diabetes mellitus, neurological causes, 
respiratory causes and urological/nephrological causes. 
• Polymicrobial infection was seen in 53.84% and monomicrobial in 46.15 % of 
the cases. Total of 40 organisms were isolated. 
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• In this study, the predominant isolates were Gram negative bacilli comprising 
67% of the isolates among which enterobacteriaceae were 34.5% and non-
fermenters 32.5% 
• Pseudomonas aeruginosa was the commonest isolate (25%) followed by 
Klebsiella pneumoniae (17.5%), Escherichia coli, Enterococcus faecalis and 
Candida spp. (15%) each. P.stutzeri comprised 5% and Klebsiella oxytoca, 
P.fluorescens and Staphylococcus aureus 2.5% each. 
• High degree of antibiotic resistance was observed among the pathogens causing 
symptomatic CAUTI. On the whole the bacterial isolates were more sensitive to 
piperacillin-tazobactam, imipenem and meropenem. 
• ESBL production was found in 25% of the strains, 37.5% of the isolates were 
positive for Amp C production and MBL was detected in 18.7% of the isolates. 
• One Staphylococcus aureus isolated was MRSA  
• There was no vancomycin resistant enterococci. 
• Among Candida isolates, non-albicans Candida spp. (83.3%) emerged as the 
predominant isolate 
• No resistance was observed among candida isolates 
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CONCLUSION 
This cross-sectional study conducted at Madras Medical College and 
Rajiv Gandhi Government General Hospital aimed at detecting one of the most common 
healthcare associated infection i.e. symptomatic catheter associated urinary tract 
infection. Development of CAUTI is common in critically ill patients. Emphasis should 
be placed on good catheter management and reducing the duration of catheterization 
rather than prophylaxis in order to reduce the incidence of catheter-related UTI. Culture 
and susceptibility testing play an important role in the management of CAUTI. 
The assessment of risk and need of catheterisation should be evaluated. The 
indwelling catheter should be used in the patients only if there is a valid indication. It 
should be removed when it is no longer indicated. If the catheter is required for more 
than 14 days, it should be replaced or alternative methods of catheterisation such as 
condom catheter, etc. should be considered. In catheterised patients, proper catheter 
bundle care should be followed.  
Antimicrobial resistance is a growing threat worldwide. There is an increasing 
resistance to third generation cephalosporins among Gram negative bacilli. The 
prevalence of extended spectrum betalactamases, Amp C betalactamases and 
metallobetalactamases constitutes a serious threat to current -lactam therapy leading to 
treatment failure. There is increase in the emergence of multidrug resistant isolates 
causing CAUTI. In order to decrease the incidence of drug resistance, prophylactic use 
of antibiotics should be discouraged. Knowledge of resistant pattern can help in 
implementing proper antibiotic therapy and infection control policy such as avoidance 
of overuse of antimicrobials, use of drugs for which pathogens are sensitive. 
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Fig 15:Antimicrobial susceptibility for Gram negative bacilli 
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Fig 19: Minimum inhibitory concentration for Vancomycin by Macrobroth dilution 
method 
 
Fig 20: MIC for vancomycin by Epsilometer test 
 
Fig 21: ESBL detection     Fig 22: Amp C detection 
   
 
 
Fig 23:Metallobetalactamase detection 
 
 
 
 
IE 
Fig 24: Germ tube test for Candida:  
Positive       Negative   
   
 
 
Fig 25: Candida Chrom Agar   Fig 26: Sugar fermentation test 
  
 
 
 
 
 
Fig 27: Sugar assimilation test 
 
Fig 28:Cornmeal Tween 80 agar: C.tropicalis   C.krusei 
 
               
Fig 29:Antifungal susceptibility test   Fig 30:MIC for antifungal drugs 
 
                
Glu 
Gal 
Raf 
APPENDIX – I 
 
ABBREVIATIONS 
  
ATCC   American Type Culture Collections  
BAP   Blood agar plate 
ESBL    Extended spectrum Beta Lactamases 
CAUTI  Catheter associated urinary tract infection 
Cel   Cellobiose 
CFU   Colony Forming Units 
CLED   Cysteine lactose electrolyte deficient  
CLSI   Clinical & Laboratory Standards Institute 
COPD   Chronic obstructive pulmonary disease 
DMSO                      Dimethyl Sulfoxide 
Dul   Dulcitol 
Gal   Galactose 
GNB   Gram negative bacilli 
Glu   Glucose 
HAI   Healthcare associated infection 
hpf   High power field 
ICU   Intensive care unit 
IMCU   Intensive medical are unit 
Ino   Inositol 
Lac   Lactose 
Mal   Maltose 
MIC                          Minimum Inhibitory Concentration  
MBL   Metallobetalactamases  
OIF   Oil immersion field 
PMN   Polymorhonuclear neutrophils 
Raff   Raffinose 
RPMI                        Rose Well Park Memorial Institute 
SDA                          Sabouraud’s Dextrose Agar 
Suc   Sucrose 
Tre   Trehalose 
UTI                           Urinary Tract Infection 
WBC   White blood cell 
Xyl   Xylose 
 
 
 
 
 APPENDIX II 
A. STAINS AND REAGENTS 
1. Gram staining 
Methyl violet (2%) -  
 
Grams Iodine         - 
Acetone                  - 
Carbol fuchsin 1% - 
l0g Methyl violet in 100ml absolute alcohol in 1 litre of 
distilled water (primary stain).  
l0g Iodine in 20g KI (fixative)  
Decolourising agent  
Secondary stain.  
 
B. MEDIA USED 
1. Mac Conkey Agar 
Peptone     20g 
Sodium taurocholate  5g 
Distilled Water    1 ltr 
Agar      20g 
2% neutral red in 50% ethanol 3.5ml 
10% lactose solution  100 ml 
Dissolve peptone and taurocholate in water by heating. Add agar and dissolve it 
in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix. Heat in 
free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes. 
2. 5% Sheep Blood Agar 
Peptone  l0g  
NaCl  5g  
Distilled water  1 Ltr  
Agar  l0g  
Dissolve ingredients in distilled water by boiling, and add 5% sheep 
blood(sterile) at 55°C adjust pH to 7.4. 
3. Sabourauds Dextrose agar 
       Dextrose  20 gm   
       Peptone   10 gm  
       Agar    20 gm  
       Distilled Water 1000 ml  
       Final pH : 6.9  
            The ingredients were dissolved by boiling. Chloramphenicol(50mg/lit) and 
Cycloheximide(500mg/lit) was added . Chloramphenicol was dissolved in 10 ml of 
95% ethanol and added to boiling medium. Cycloheximide was dissolved in 10 ml of 
acetone and added to the boiling medium. It was autoclaved at 121°C for 15 minutes 
and dispensed in sterile tubes and allow to cool in slanted position.  
4. Mueller Hinton Agar 
Beef Infusion  300ml 
Caesein Hydrolysate 17.5g 
Starch   1.5g 
Agar   20 g 
Distilled Water  1ltr 
ph = 7.4 
Sterilise By autoclaving at 121°C for 20 minutes. 
5. Corn meal  tween 80 agar  medium 
 Cornmeal    : 8gm 
Agar              : 4gm 
Tween 80(1%): 2ml 
Distilled water: 200ml 
                    Heat cornmeal and water at 60ºC for 1 hour and filter through filter 
paper.Add distilled water to make it 200ml and then add agar.Tween 80 is then 
added.Autoclave it at 121 ºC for 15 mins. 
6. Yeast nitrogen base medium 
Part A : Agar 40gms/lit 
Part B : Yeast nitrogen base 6.7gms/lit 
             40 grams of part A media is suspended in 900 ml of distilled water. Heat 
to boiling to dissolve the medium completely. Autoclave at 121º C for 12 minutes. 
Cool to 50° C and mixed with sterile part B solution aseptically. 
7. Candida chromagar medium 
Ingredients                                              Gms/L 
Peptone                                                     15.00 
Yeast extract                                              4.00 
Dipotassium hydrogen phosphate             1.00 
Chromogenic mixture                               7.22 
Chloramphenicol                                      0.50 
Agar                                                         15.00 
Final pH: 6.3        
   42.72 grams of media is suspended in 1000 ml of distilled water. Heat to boiling to 
dissolve the medium  completely. Do not autoclave. Cool to 50° C and pour in sterile 
petridish. 
8. Supplemented mueller hinton agar  
Ingredients     Gms / Litre 
Beef extract                                                   3.000 
Casein acid hydrolysate                                17.500 
Starch                                                            1.500  
Agar                                                             17.000 
Final pH (at 25°C)  7.3±0.2 
           38grams of media is suspended in 1000 ml of distilled water.  Add 20gm of 
glucose(2%) and  methylene blue (0.5µg/ml) is added. Dissolve  the  medium 
completely. Dispense and sterilize by autoclaving at 115-121°C for 10 minutes. Do not 
overheat. 
9.  RPMI 1640 MEDIUM [With glutamine and without bicarbonate] 
     Obtained commercially as a dehydrated powder. Suspend 8.4gms of media in 900ml 
of sterile distilled water. Stir it to completely dissolve the medium do not heat. Sterilize 
the medium by filtration. Final pH=7.0. 
C. REAGENTS & MEDIA REQUIRED FOR BIOCHEMICAL 
IDENTIFICATION 
1. Oxidase Reagent 
Tetra Methyl P-Phenylene Diamine Dihyrochloride- 1% Aqueous Solution 
2. Catalase test 
3% Hydrogen Peroxide 
3. Kovac's Reagent 
Amyl Or Isoamyl Alcohol   150ml  
Para Dimethyl Amino Benzaldehyde  10g  
Concentrated Hydrochloric Acid  50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small quantities and 
store in the refrigerator. Shake gently before use. 
4. Christensen's Urease Test Medium 
 Peptone  1g 
 Sodium Chloride  5g 
 Dipotassium Hydrogen Phosphate  2g 
 Phenol Red  6ml 
 Agar  20g 
 Distilled Water  1 Ltr 
 10% Sterile Solution Of Glucose  10ml 
 Sterile 20% Urea Solution  100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without 
glucose and urea, adjust to ph 6.8-6.9 and sterilize by autoclaving in a flask at 121°c for 30min. 
Cool to about 50°C, add the glucose & urea, and tube the medium as slopes. 
5. Simmon's Citrate Medium 
Koser's Medium   1 Ltr 
Agar   20 g 
Bromothymol Blue 0.2%      40ml  
Dispense, autoclave at 121°c for 15 min and allow to set as slopes. 
 
6. Triple Sugar Iron Medium 
Beef Extract   3g 
Yeast Extract   3g 
Peptone   20g 
Glucose   1g 
Lactose   10 g 
Sucrose   10g 
Ferric Citrate   0.3g 
Sodium Chloride   5g 
S Odum Thiosulphate   0.3g 
Agar   12g 
Phenol Red 0.2% Solution   12ml 
Distilled Water   1 Ltr 
 Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize at 121°c for 
15 min and cool to form slopes with deep butts. 
7.  Glucose Phosphate Broth 
Peptone   5g 
Dipotassium Hydrogen Phosphate   5g 
Water   1 ltr 
Glucose 10% Solution   50ml 
 Dissolve the peptone and phosphate and adjust the ph to 7.6. Filter dispense in 5ml 
amounts and sterilize at 121°c for 15min. Sterilize the glucose solution by filtration and add 
0.25ml to each tube. 
8. Peptone Water Fermentation Test Medium. 
 To the basal medium of peptone water, add sterilised sugars of 1% indicator 
bromothymol blue with durham's tube. Basal medium peptone water sugar solutions: 
Sugar       1ml 
Dislilled Water     100ml  
Ph = 7.6. 
9.Potassium Nitrate Broth 
Potassium Nitrate (KNO3) 0.2gm 
Peptone 5.0gm 
          DistilledWater 100ml 
     The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclaved. 
 
10.Phenyl Alanine Deaminase Test 
Yeast Extract 3g 
Dl-Phenylalamine 2 g  
Disodium Hydrogen Phosphate L g  
Sodium Chloride 5 g  
Agar 12g 
Distilled Water 1 Lr 
Ph 7.4 
     Distributed in tubes and sterilized by autoclaving at 121° c for 1 5 minutes, allowed 
to solidify as long slopes. 
11. Sugar Fermentation Medium 
Peptone 15g 
Andrade's Indicator 10 ml 
Sugar to be tested 20g 
Water 1 litre 
Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to 
Which sufficient 1m sodium hydroxide has been added to turn the colour of the solution 
yellow. 
Dissolve the peptone and andrade's indicator in 1 litre of water and add 20g of 
the sugar; sugars to be tested generally include glucose, sucrose, lactose and maltose. 
Distribute 3ml amounts in standard test tubes containing an inverted durham’s tube. 
Sterilize by steaming at 100 ° C for 30 minutes on 3 consecutive days. 
ANNEXURE I: CERTIFICATE OF APPROVAL 
 
ANNEXURE II 
PROFORMA 
• Name :                                                                        IP no: 
• Age:                                                                           Ward:      
• Sex:       Date of admission: 
• Occupation: 
• Address: 
Indication for Foley’s Catheter: 
Date of Foley’s catheter insertion: 
Date of Foley’s catheter removal/change: 
Total catheter days: 
Aseptic technique of insertion (Y/N): 
Disconnection of drainage system: 
Faulty catheter care(Y/N): 
Development of following symptoms: 
Symptom Day of development/ 
presence 
Sample collection 
day 
Fever   
Chills   
Suprapubic pain   
Back pain (costovertebral angle pain):   
Dysuria                   
Frequency   
Urgency   
 Present history (medical & surgical): 
Past history (medical & surgical):  
Associated impaired state: 
• Tuberculosis  
• Chronic steroid intake 
• Diabetes mellitus 
• HIV  
• Other:  
Other evidence of infection found on direct exam or by diagnostic tests: 
Provisional diagnosis: 
Laboratory evaluation: 
Biochemical parameters: 
 Plasma glucose levels 
  Blood urea 
 Creatinine 
Hematological investigations: 
• TC 
• DC 
• Hb estimation 
• ESR 
• Other tests: 
Microbiological investigation: 
Sample 
(catheterized 
urine) collection 
date/day 
Apperance 
of urine 
Direct Examination Culture 
Gram 
stain 
Wet 
mount 
Dipstick test for 
urine nitrite/ 
leukocyte esterase 
MAC BAP 
       
       
       
       
       
       
 
Colony Morphology 
In  MAC : 
      BAP : 
Gram Staining Reaction: 
Bacterial isolate: 
Motility of the Organism: 
Catalase 
Oxidase 
Coagulase:       Slide coagulase                                                        
                        Tube coagulase 
Bile esculin 
Biochemical Reactions: 
Indole Test 
Triple sugar iron media 
Fungal (candida) isolate: 
Germ tube test: 
Chrom agar:  
 
Sugar assimilation test:
 
 
Sugar fermentation test: 
 
 
Simmons’ citrate medium 
Christensen’s urease medium 
Other tests: 
Other tests: 
Organism(s) isolated:  
Antibiogram:  
 
ANNEXURE III 
CONSENT FORM 
STUDY TITLE: 
“A study on microbiological profile of symptomatic catheter associated urinary 
tract infection in intensive care unit setup in a tertiary care hospital’’ 
Name:          Date: 
Age :                IP No :  
 Sex :        Project Patient No. : 
Documentation of the informed consent 
       I, _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. I  
hereby give my consent to be included as a participant in “A study on 
microbiological profile of symptomatic catheter associated urinary tract infection 
in intensive care unit setup in a tertiary care hospital’’ 
I have read and understood this consent form and the information provided to me. 
1. I have had the consent document explained to me. 
2. I have been explained about the nature of the study. 
3. I have been explained about my rights and responsibilities by the investigator.  
4. I have been informed the investigator of all the treatments I am taking or have taken 
in the past ________ months including any native (alternative) treatment. 
5. I have been advised about the risks associated with my participation in this study. 
6. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms. 
7. I have not participated in any research study within the past ________ month(s). 
8. I am aware of the fact that I can opt out of the study at any time without having to 
give my reason and this will not affect my future treatment in this hospital. 
9. I am also aware that the investigator may terminate my participation in the study at 
any time, for any reason, without any consent. 
10. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC. I understand that they are publicly presented. 
11. I have understand that my identity will be kept confidential if my data are publicly 
presented. 
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has 
been clearly explained to me and understood by me, I will be given a copy of this 
consent document. 
For  participants: 
Name and signature / thumb impression of the participant  
OR legal representative if participant  incompetent/For age 10-17 yrs-Name& 
signature of the parent/guardian. 
Name ___________________________________ 
Signature_________________________  
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ___________________________________ 
Signature_________________________  
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name ___________________________________  
Signature_________________________  
Date________________ 
  
 ANNEXURE IV 
  
  
 
MASTER CHART 
   
  
  
Gender
M/F Y N 3 5 7 10 14 21 Age ≥ 50 yrs Female sex
Duration of 
catheterisati
on ≥ 10 days
Diabetes 
mellitus
Neurological 
causes
Respiratory 
causes
Urological/N
ephrological 
causes
Steroid
Other 
immunocom
promised 
conditions
FauLty 
catheter care
Amp Ak Gm Nt Nx Cotri Ctx Caz PT Ipm Mrp Tetra Pen Vanco HLG Cx Flu Vori Ampho Itra
1 131216 58 M 8 monitor urinary output Y N Y N N N N N N N N N
2 132056 52 F 14 monitor urinary output Y Y Y Y Y Y N N Y N N N N E.coli R R S S R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
Enterococcus faecalis ─ * * R R * * * ─ ─ ─ R R S S * ─ ─ ─ ─ ─ ─ ─ ─ ─
3 131668 70 M 10 monitor urinary output Y N Y N Y N N Y N N N N
4 132881 20 F 9 monitor urinary output Y N N Y N N N N N N N N
5 132282 32 F 9 monitor urinary output Y N N Y N N N N N N N N
6 132341 65 F 8 monitor urinary output Y N Y Y N Y N N N N N N
7 131564 68 M 8 monitor urinary output Y N Y N N N Y N N N N N
8 132762 45 M 10 monitor urinary output Y Y Y N N Y N Y N N N N N K.pneumoniae * R R R R R R R R R R R ─ ─ ─ R ─ ─ ─ ─ N N Y Y ─
9 132844 21 M 8 monitor urinary output Y N N N N N N N N N N N
10 58 33 M 8 monitor urinary output Y N N N N N N N N N N N
11 94766 20 F 21 monitor urinary output Y Y Y N Y Y N Y N N N N N K.pneumoniae * R R R R R R R R R R R ─ ─ ─ R ─ ─ ─ ─ N N Y Y ─
Enterococcus faecalis ─ * * S S * * * ─ ─ ─ R R S R * ─ ─ ─ ─ ─ ─ ─ ─ ─
12 253 35 M 10 monitor urinary output Y N N N Y N N N N N N N
13 9480 80 F 10 monitor urinary output Y Y Y Y Y Y Y N N N N N N P.aeruginosa * R R R R * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
Candida krusei ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ * S S S ─ ─ ─ ─ ─
14 6296 53 M 7 monitor urinary output, relieve 
urinary retention
Y N Y N N N N N Y N N N
15 10342 30 F 9 monitor urinary output Y N N Y N Y N N N N N N
16 10019 38 M 7 monitor urinary output Y N N N N N N N N N N N
17 10557 39 F 8 monitor urinary output Y N N Y N N N N N N N N
18 132256 45 M 14 monitor urinary output Y Y Y N N Y N Y N N N N N Staphylococcus aureus ─ R R S R R ─ ─ ─ ─ ─ S R S ─ R ─ ─ ─ ─ ─ ─ ─ ─ Y
19 10302 27 M 7 monitor urinary output Y N N N N N N N N N N N
20 7766 72 M 7 monitor urinary output Y N Y N N N N N N N N N
21 8638 45 F 14 monitor urinary output Y Y Y N Y Y N Y N N N N N P.stutzeri * R R R R R R R R S S R ─ ─ ─ R ─ ─ ─ ─ N Y N N ─
22 19425 38 M 9 monitor urinary output Y N N N N Y N N N N N N
23 10144 33 M 7 monitor urinary output Y N N N N N N N N N N N
24 667 67 F 14 monitor urinary output Y Y Y Y Y Y Y Y N N N N N Enterococcus faecalis ─ * * S R * * * ─ ─ ─ R R S S ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
25 9407 33 F 10 monitor urinary output Y N N Y Y N Y N N N N N
26 8640 24 M 14 monitor urinary output Y Y Y N N Y N Y N N N N N Candida albicans ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ S S S S ─ ─ ─ ─ ─
Enterococcus faecalis ─ * * S S * * * ─ ─ ─ S R S S S ─ ─ ─ ─ ─ ─ ─ ─ ─
27 8986 52 F 14 monitor urinary output Y Y Y Y Y Y N N N N N N N P.fluorescens * R R R R R R R S S S R ─ ─ ─ S S ─ ─ ─ Y N N N ─
K.pneumoniae * R R S R R R R R S S R ─ ─ ─ R ─ ─ ─ ─ N Y N N ─
28 10589 48 M 9 monitor urinary output Y N N N N N N N N Y N N
29 11026 19 F 13 monitor urinary output Y N N Y Y N N N N Y Y N
30 6749 74 M 10 monitor urinary output Y Y Y Y N Y N N N N N N N K.oxytoca R R R S R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
31 9926 32 F 16 monitor urinary output Y N N Y Y N N N N N N N
32 11807 62 M 6 monitor urinary output Y N Y N N Y N N N N Y N
33 11459 23 F 14 monitor urinary output Y Y Y N Y Y Y N N N N N N E.coli R R R R R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
Candida parapsilosis ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ S S S S ─ ─ ─ ─ ─
34 12086 25 F 7 monitor urinary output Y N N Y N N N N N Y Y N
35 12221 34 F 9 monitor urinary output Y N N Y N N N N N N N N
36 13131 29 F 8 monitor urinary output Y N N Y N N N N N N N N
37 13129 20 M 14 monitor urinary output Y Y Y N N Y N N Y N N N N P.aeruginosa * R R R S * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
38 13256 45 M 9 monitor urinary output Y N N N N N N N N N N N
39 11787 41 M 14 monitor urinary output Y Y Y N N Y N N Y N N N N P.aeruginosa * R S R S * * S S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
Candida tropicalis ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ S S S S ─ ─ ─ ─ ─
40 10738 65 F 8 monitor urinary output Y N Y Y N N N N N N N N
41 13165 61 M 9 monitor urinary output Y N Y N N N N N N N N N
42 12231 28 F 8 monitor urinary output Y N N Y N N N N N N N N
43 16431 27 F 14 monitor urinary output Y Y Y N Y Y N N N N N N N Enterococcus faecalis ─ * * S R * * * ─ ─ ─ R R S S ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
44 11166 26 M 7 monitor urinary output Y N N N N N N N N N N N
45 71931 52 M 8 monitor urinary output Y N Y N N Y Y N N N N N
46 12684 29 M 8 monitor urinary output Y N N N N N N N N N N N
47 11041 35 F 7 monitor urinary output Y N N Y N N N N N N N N
48 12143 35 F 14 monitor urinary output Y Y Y N Y Y N N N N Y Y N K.pneumoniae * R R R R R R R R S S R ─ ─ ─ S ─ ─ ─ ─ N Y N N ─
P.stutzeri * R R R R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
49 11822 68 F 8 monitor urinary output Y N Y Y N Y N Y N N N N
50 7139 34 F 14 monitor urinary output Y Y Y N Y Y Y N N N Y N N E.coli R R R R R R R R R S S R ─ ─ ─ R ─ ─ ─ ─ N Y N N ─
K.pneumoniae * R R R R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
51 11057 54 M 10 monitor urinary output Y N Y N Y N Y N N N N N
52 13824 55 M 8 monitor urinary output Y N Y N N N N N N N N N
53 14510 45 F 10 monitor urinary output Y N N Y Y N Y N N N N N
54 14644 32 M 14 monitor urinary output Y Y Y N N Y Y N Y N N N N P.aeruginosa * R R R R * * R R S S * ─ ─ ─ R ─ ─ ─ ─ N Y N N ─
C.glabrata ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ S S S S ─ ─ ─ ─ ─
55 65230 38 M 7 monitor urinary output Y N N N N N N N N N N N
56 166211 22 F 9 monitor urinary output Y N N Y N N N N N N N N
57 11214 35 M 10 monitor urinary output Y N N N Y N Y N N N N N
58 4899 45 F 21 monitor urinary output, relieve 
urinary retention
Y Y Y N Y Y Y N N Y N N N P.aeruginosa * R R R R * * R R R R * ─ ─ ─ R ─ ─ ─ ─ N N Y Y ─
K.pneumoniae * R R R R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
59 13894 55 M 10 monitor urinary output Y N Y N Y N Y N N N N N
60 17400 30 M 8 monitor urinary output Y N N N N N N N N N N N
61 17351 27 M 7 monitor urinary output Y N N N N N N N N N N N
62 15889 42 F 14 monitor urinary output Y Y Y N Y Y N N Y Y N N N Enterococcus faecalis ─ * * R S * * * ─ ─ ─ R R S S ─ ─ ─ ─ ─ ─ ─ ─ ─ ─
63 16330 50 M 8 monitor urinary output Y N Y N N N Y N N N N N
64 17385 21 M 8 monitor urinary output Y N N N N N N N N N N N
65 16839 30 F 8 monitor urinary output Y N N Y N N N N N N N N
66 13129 51 F 10 monitor urinary output Y Y Y Y Y Y N N Y N N N N P.aeruginosa * R R R R * * R R S S * ─ ─ ─ R ─ ─ ─ ─ N Y N N ─
67 17343 33 F 9 monitor urinary output Y N N Y N N N N N N N N
68 17369 18 M 10 monitor urinary output Y N N N Y N N N N N N N
69 16805 46 M 9 monitor urinary output Y N N N N N N N N N N N
70 15959 40 M 14 monitor urinary output Y Y Y N N Y Y Y N N N Y N P.aeruginosa * R R R R * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
71 16400 65 M 10 monitor urinary output Y N Y N Y N N N N N N N
72 16681 46 M 10 monitor urinary output Y N N N Y N N N N N N Y
73 20451 25 M 9 monitor urinary output Y N N N N N N N N N N N
74 19249 20 M 8 monitor urinary output Y N N N N N N N N N N N
75 8981 19 F 8 monitor urinary output Y N N Y N N N N N N N N
76 20269 31 M 14 monitor urinary output, relieve 
urinary retention
Y Y Y N N Y N N N Y N N N P.aeruginosa * R R R R * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
C.tropicalis ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ S S S S ─ ─ ─ ─ ─
77 20070 55 F 9 monitor urinary output Y N Y Y N Y N N N N N N
78 20001 18 F 9 monitor urinary output Y N N Y N N N N N N N N
79 20113 25 M 8 monitor urinary output Y N N N N N N N N N N N
80 19301 42 M 8 monitor urinary output Y N N N N N N N N N N N
81 19335 40 M 10 monitor urinary output Y N N N Y N N N N N N N
82 14588 68 F 21 monitor urinary output, relieve 
urinary retention
Y Y Y Y Y Y N Y N Y N N N E.coli R R R S R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
83 20094 19 F 9 monitor urinary output Y N N Y N N N N N N N N
84 19525 58 M 9 monitor urinary output Y N Y N N N N N N N N N
85 19506 32 F 8 monitor urinary output Y N N Y N N N N N N N N
86 16706 22 M 9 monitor urinary output Y N N N N N N N N N N N
87 20968 45 F 14 monitor urinary output Y Y Y N Y Y Y Y Y N N N N P.aeruginosa * R R R R * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
E.coli R R R S R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
88 51527 35 F 10 monitor urinary output Y N N Y Y N N N N N N N
89 52060 20 M 12 monitor urinary output Y N N N Y N N Y N N N N
90 20480 47 M 8 monitor urinary output Y N N N N N N N N N N N
91 50432 42 M 10 monitor urinary output Y Y Y N N Y Y N N N N N Y K.pneumoniae * R R R S R R R S S S S ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
92 45141 27 F 8 monitor urinary output Y N N Y N N N N N N N N
93 48796 42 M 11 monitor urinary output Y N N N Y N N N N N N N
94 50439 46 M 12 monitor urinary output Y N N N Y N N N N N N N
95 47335 74 M 14 monitor urinary output Y Y Y Y N Y Y Y N N N N N P.aeruginosa * S R R R * * R S S S * ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
E.coli R R R R R R R R S S S R ─ ─ ─ S ─ ─ ─ ─ Y N N N ─
96 49509 23 F 9 monitor urinary output Y N N Y N N N N N N N N
97 65352 20 M 9 monitor urinary output Y N N N N N N N N N N Y
98 64550 24 M 8 monitor urinary output Y N N N N N N N N N N N
99 64818 40 M 9 monitor urinary output Y N N N N N N Y N N N N
100 64267 35 F 8 monitor urinary output Y N N Y N N N N N N N N
ESBL Amp C MBL MRSA
Total 
catheter 
days
Antimicrobial susceptibility
Indication for 
catheterisation
Risk factors present
CarbapenemaseS.no. IP no. Age Organism isolated
Day of development of 
Symptomatic CAUTI
Symptomatic 
CAUTI
Indication 
valid (Y/N)
KEY TO MASTER CHART  
Ak  Amikacin 
Amp  Ampicillin 
Ampho Amphotericin B 
Cotri  Cotrimoxazole 
Ctx  Cefotaxime 
Caz  Ceftazidime 
Cx  Cefoxitin 
ESBL  Extended spectrum betalactamase 
F   Female  
Flu  Fluconazole 
Gm  Gentamicin 
HLG  High level gentamicin 
Ipm  Imipenem 
Itra  Itraconazole 
M   Male  
MBL  Metallobetalactamase 
MRSA Methicillin resistant Staphylococcus aureus 
Mrp  Meropenem 
Nor  Norfloxacin 
Nit  Nitrofurantoin 
Pen  Penicillin 
PT  Piperacillin-tazobactam 
Y   Yes  
N   No  
R   Resistant 
S  Sensitive 
Tetra  Tetracycline 
Van  Vancomycin 
Vori  Voriconazole 
*    intrinsic resistance 
-  not applicable 
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